

# **in vivo**

**International Journal of Experimental and  
Clinical Pathophysiology and Drug Research**

ISSN: 0258-851X

**Volume 22  
2008**

**INDEX**

## Editorial Board

- N.J. AGNANTIS, *Department of Pathology, University of Ioannina, Ioannina, Greece*  
D. ANDERSON, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*  
V. BARAK, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*  
M.H. BARCELLOS-HOFF, *Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA*  
Y. BECKER, *Department of Molecular Biology, Hebrew University of Jerusalem, Jerusalem, Israel*  
K. BEIER, *Department of Histology, University of Basel, Basel, Switzerland*  
S. BEN-EFRAIM, *Department of Human Microbiology, University of Tel-Aviv, Tel-Aviv, Israel*  
M. BERGQVIST, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*  
R. BJERKVIG, *Department of Anatomy and Cell Biology, University of Bergen, Bergen, Norway*  
B. BODEY, *Department of Pathology, University of Southern California, Reseda, CA, USA*  
D.A. BUTTERFIELD, *Department of Biological and Physical Chemistry, University of Kentucky, Lexington, KY, USA*  
M. CARAGLIA, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*  
P. CHANDRA, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*  
J.-G. CHUNG, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*  
L.A. COHEN, *Northampton, MA, USA*  
A.I. CONSTANTINOU, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*  
J.G. CORY, *Department of Biochemistry and Molecular Biology, East Carolina University, Greenville, NC, USA*  
T. DALIANIS, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*  
I. DAMJANOV, *Department of Pathology, The University of Kansas, Kansas City, KS, USA*  
G. DELICONSTANTINOS, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*  
D.T. DENHARDT, *Department of Cell Biology and Neurosciences, Rutgers University, Piscataway, NJ, USA*  
W. DEN OTTER, *Department of Biochemistry, University of Utrecht, Utrecht, The Netherlands*  
K. DE MEIRLEIR, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*  
L. DE RIDDER, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*  
E.P. DIAMANDIS, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*  
J.F. DORÉ, *Centre Léon Berard, Lyon, France*  
T. EFFERTH, *Helmholtz Graduate School for Cancer Research, German Cancer Research Center, Heidelberg, Germany*  
I. EMBER, *Department of Public Health, University of Pécs Medical School, Pécs, Hungary*  
W. ENGSTRÖM, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*  
M. ESKELINEN, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*  
J.A. FERNANDEZ-POL, *Metalloproteomics, LLC, Chesterfield, MO, USA*  
S. FERRONE, *Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA*  
G. FIORENTINI, *Department of Oncology, San Giuseppe – Antica Sede Hospital, Empoli (FI), Italy*  
P.B. FISHER, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*  
I. FREITAS, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*  
M. FRIEDRICH, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*  
R.E. FRIEDRICH, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*  
R. GANAPATHI, *Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA*  
D.H. GILDEN, *Department of Neurology, University of Colorado, Denver, CO, USA*  
G. GITSCH, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*  
J.S. GREENBERGER, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*  
J.W. GREINER, *National Cancer Institute, NIH, Bethesda, MD, USA*

- C.J. GRUBBS, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*  
F. GUADAGNI, *IRCCS San Raffaele, Rome, Italy*  
F. HALBERG, *Chronobiology Laboratories, University of Minnesota, Minneapolis, MN, USA*  
T. HAMAOKA, *Department of Oncology, Osaka University, Graduate School of Medicine, Osaka, Japan*  
R.R. HARDY, *Fox Chase Cancer Center, Philadelphia, PA, USA*  
J. HAU, *Department of Comparative Medicine, University of Copenhagen, Denmark*  
M. HAUER-JENSEN, *Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA*  
G.H. HEPPNER, *Department of Immunology, Michigan Cancer Foundation, Detroit, MI, USA*  
K. HIBI, *Department of Surgery, Showa University Fujigaoka Hospital, Yokohama, Japan*  
S.A. IMAM, *Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA*  
C.G. IOANNIDES, *Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*  
J.R. IZBICKI, *Chirurgische Universitätsklinik, Universitätskrankenhaus Hamburg, Germany*  
K.S. JEONG, *Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea*  
M. KOUTSILIERIS, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*  
G.R.F. KRUEGER, *Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany*  
T. KUBOTA, *Department of Surgery, Keio University School of Medicine, Tokyo, Japan*  
S.A. LAMPRECHT, *Department of Medicine, Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, NY, USA*  
G. LANDBERG, *Department of Laboratory Medicine, Lund University, Lund, Sweden*  
I. LELONG-REBEL, *Lab. de Cancérologie Exp. et de Radiobiologie, IRCAD, Strasbourg, France*  
J. LEROY, *IRCAD, University of Strasbourg, France*  
B. LÉYLAND-JONES, *Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA*  
W. LICHTENEGGER, *Charité Campus Virchow-Klinikum, Berlin, Germany*  
P. MADARNAS, *Department of Pathology, University of Sherbrooke, Québec, Canada*  
H. MAEDA, *Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan*  
M. MAREEL, *Laboratory of Experimental Cancerology, State University, Ghent, Belgium*  
G. MARTORANA, *Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy*  
D. P. MIKHAILIDIS, *Department of Chemical Pathology, The Royal Free Hospital, London, UK*  
H. C. MORSE III, *Laboratory of Immunopathology, NIH, Bethesda, MD, USA*  
N. MOTOHASHI, *Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan*  
R. M. NAGLER, *Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel*  
R. NARAYANAN, *Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA*  
K. NILSSON, *Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden*  
K. R. NORUM, *Institute for Nutrition Research, University of Oslo, Oslo, Norway*  
R. F. NOVAK, *Institute of Chemical Toxicology, Wayne State University, Detroit, MI, USA*  
J. O'KELLY, *Division of Hematology-Oncology, Cedar Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA*  
Y. OKADA, *Department of Cell Physiology, National Institute for Physiological Sciences, Okazaki, Japan*  
M. PAGÉ, *Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada*  
P. PANTAZIS, *Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA*  
M.-F. POUPON, *Institut Curie, Section de Recherche, Paris, France*  
F.M. ROBERTSON, *Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*

- D. RUBELLO, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*  
C.A. RUBIO, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*  
G.R. RUTTEMAN, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*  
H. SAKAGAMI, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*  
G. SAVA, *Institutes of Biological Research, Fondazione Callerio-Onlus, Trieste, Italy*  
K.J. SCANLON, *International BioScience, Altadena, CA, USA*  
D. SCHIFFER, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*  
L.D. SHULTZ, *The Jackson Laboratory, Bar Harbor, ME, USA*  
G. SICA, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*  
R.M. SNAPKA, *Department of Radiology, The Ohio State University, Columbus, OH, USA*  
G.-I. SOMA, *Institutes for Health Sciences, Tokushima Bunri University, Tokushima, Japan*  
T.A. SPRINGER, *Department of Pathology, Harvard Medical School, Boston, MA, USA*  
T. TAKAHASHI, *Aichi Cancer Center, Nagoya, Japan*  
N. TANAKA, *Research Institute, Daiichi Seiyaku Co. Ltd., Tokyo, Japan*  
H. TAPIERO, *Biomedicine & Pharmacotherapy, ICIG, Hopital Paul-Brousse, Villejuif, France*  
K.D. TEW, *Fox Chase Cancer Center, Philadelphia, PA, USA*  
K.D. TEW, *Fox Chase Cancer Center, Philadelphia, PA, USA*  
T. TOGE, *Research Institute of Radiation Biology, Hiroshima University, Hiroshima, Japan*  
B. TRIBUKAIT, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*  
C. TROPÉ, *Radiumhospitalet, Oslo, Norway*  
P. TSONIS, *Department of Biology, University of Dayton, OH, USA*  
T. TSURUO, *Japan Foundation for Cancer Research, Cancer Chemotherapy Center, Tokyo, Japan*  
J. VADGAMA, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*  
A. VECCHIONE, *Universita degli Studi di Roma "La Sapienza", Rome, Italy*  
N. WATANABE, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*  
W. WEBER, *Clinical Cancer Etiology Unit, Basel, Switzerland*  
L.M. WEINER, *Fox Chase Cancer Center, Philadelphia, PA, USA*  
J.A. WERNER, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*  
H. YAMAUE, *Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan*  
S. YLÄ-HERTTUALA, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*  
H. YOSHIDA, *Department of Pathology, Kagoshima University, Kagoshima, Japan*

## Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 22, 2008.

- Aase og Ejnar Danielsens Fond, Lyngby, Denmark  
Academy of Athens, Greece  
ACT 29 Anillo Bicentenario Santiago de Chile  
Afyon Kocatepe University, Afyonkarahisar, Turkey  
Alberta Cancer Board and Foundation, Edmonton, Alberta, Canada  
Alma Mater Studiorum-Università di Bologna “Ricerca Fondamentale Orientata”, Bologna, Italia  
Asan Institute for Life Sciences, Seoul, Korea
- Beckett Fond, Denmark
- Cassa di Risparmio di Bologna, Italy  
Center of Instrumental Analysis, University of Patras, Greece  
Chen-Han Foundation for Education, Taipei, Taiwan, R.O.C.  
China Medical University, Taichung city, Taiwan, R.O.C.  
Chulabhorn Research Institute, Bangkok, Thailand  
Council of Science & Technology, Uttar Pradesh, Lucknow, India
- Dagmar Marshall Fond, Denmark  
Danone-Stiftung, Germany  
Department of Otorhinolaryngology , University of Schleswig-Holstein, Lübeck, Germany  
DiLab, Lund, Sweden
- FONDECYT, Santiago de Chile  
Foundation for Cancer Research Szeged, Hungary  
Foundation for Promotion of Cancer Research, Japan  
Fundação para a Ciência e a Tecnologia (FCT), Portugal  
FUTURA-Onlus, Italy
- Gong Bih Enterprise Co., Ltd., Yun-Lin Hsien, Taiwan, R.O.C.  
Greek Ministry of Education
- H.W. and J. Hector-Stiftung, Weinheim, Germany  
High-Technology Center, Kanazawa Medical University, Japan
- Institute of Hygiene and Tropical Medicine (IHMT), Portugal  
Institute of Pharmacy, Johannes Gutenberg-University, Germany
- International Society for the Study of Comparative Oncology, Inc. (ISSCO) Silver Spring, MD, U.S.A.  
Italian Ministry of Health
- Japan Society for the Promotion of Science (JSPS)
- Kampo Medicine, Japan  
Karolinska Institute, Stockholm, Sweden  
Kodama Memorial Fund Medical Research, Japan  
Korea Science and Engineering Foundation (KOSEF)  
Korean Government (MOST)
- Laboratory for Experimental Surgery and Surgical Research, School of Medicine, University of Athens, Greece  
LLUMC Department of Radiation Medicine, Loma Linda University Medical Center, U.S.A.  
Long-range Research Initiative (LRI), Japan Chemical Industry Association
- Mildred-Scheel-Stiftung (Deutsche Krebshilfe), Germany  
Ministero dell’Istruzione dell’Università e della Ricerca, Italy  
Ministry of Economic Affairs of the Republic of China, Taiwan, R.O.C.  
Ministry of Education, Culture, Sports, Science and Technology, Japan  
Ministry of Health, Labour and Welfare, Japan  
Ministry of Science and Technology, Korea  
Monika-Kutzner-Stiftung, Germany
- National Aeronautics and Space Administration (NASA), Washington, DC, U.S.A.  
National Natural Science Foundation of China  
Natural Sciences and Engineering Research Council of Canada  
Nihon-Boehringer Ingelheim Co. Ltd., Tokyo, Japan  
Nissui Co. Ltd., Tokyo, Japan
- Office of Science, Oak Ridge, TN, U.S.A.
- Polyene Project Ltd. , Tokyo, Japan
- Rudolf-Bartling-Stiftung, Germany  
Rural Development Administration, Republic of Korea
- Second University of Naples, Italy  
Singapore National Medical Research Council

State Scholarships Foundation of Greece	U.S. Army Medical Research Acquisition Activity (USAMRAA)
Swedish Research Council	U.S. Department of Energy, Washington, DC, U.S.A.
Szeged Foundation for Anticancer Research, Hungary	University of California, U.S.A.
The International Society for the Study of Comparative Oncology, Inc. (ISSCO, President HE Kaiser) Silver Spring, MD, U.S.A.	University of Pavia, Italy
The Kidney Foundation, Japan	Vertex Pharmaceuticals Incorporated, Cambridge, MA, U.S.A.
The Novo Nordic Foundation and Clinical Institute, Aarhus University, Denmark	Wake Forest University, NC, U.S.A..
The Research Support Unit, İstanbul University, Turkey	Werner-and-Klara-Kreitz-Stiftung, Germany
The Susan G. Komen Breast Cancer Foundation, San Diego, CA, U.S.A.	Yashima Co. Ltd., Tokyo, Japan
Tzu Chi General Hospital, Hualien, Taiwan, R. O. C.	

## Contents, Volume 22, 2008

### Number 1

#### *Experimental Studies*

- TGF-beta Antisense Oligonucleotides Modulate Expression of Matrix Metalloproteinases in Isolated Fibroblasts from Radiated Skin. K. RIEDEL, T. KREMER, H. RYSSEL, F. RIEDEL, U.R. GOESSLER, E. KOELLENSPERGER, G. GERMANN, M. SAUERBIER (*Ludwigshafen; Mannheim, Germany*) ..... 1
- The Frequency of Gastric Pyloric Cells with Glassy Cytoplasm in Baboons. A Comparison with Human Subjects. C.A. RUBIO, E.J. DICK Jr., M.L. MILLER, G.B. HUBBARD (*San Antonio, TX; Cincinnati, OH, USA*) ..... 9
- Suppressive Activity of Epinastine Hydrochloride on Eosinophil Activation *In Vitro*. Y.-I. MOCHIZUKI, A. FURUTA, A. FURUYA, K.-I. KANAI, K. ASANO, H. SUZAKI (*Tokyo; Yokohama, Japan*) ..... 13
- Growth Inhibition and Induction of Apoptosis by 2-Methoxyestradiol in Rat Osteosarcoma and Malignant Fibrous Histiocytoma Cell Lines. H. FUJII, K. HONOKI, T. TSUJIUCHI, A. KIDO, K. YOSHITANI, Y. TAKAKURA (*Nara; Osaka, Japan*) ..... 21
- Characterization of a Rabbit Antihuman Mechano Growth Factor (MGF) Polyclonal Antibody against the Last 24 Amino Acids of the E Domain. A. PHILIPPOU, A. STAVROPOULOU, A. SOURLA, N. PISSIMISSIS, A. HALAPAS, M. MARIDAKI, M. KOUTSILIERIS (*Athens, Greece*) ..... 27
- Changes of Glucocorticoid Receptor Expression in the Nasal Polyps of Patients with Chronic Sinusitis Following Treatment with Glucocorticoid. S. WATANABE, H. SUZAKI (*Tokyo, Japan*) ..... 37
- Cutaneous T-cell Lymphoma in an African Hedgehog (*Atelerix albiventris*). E.P. SPUGNINI, A. PAGOTTO, F. ZAZZERA, A. D'AVINO, G. CARUSO, G. CITRO, A. BALDI (*Rome; Naples, Italy*) ..... 43
- Adjuvant Electrochemotherapy for Incompletely Excised Anal Sac Carcinoma in a Dog. E.P. SPUGNINI, I. DOTSINSKY, N. MUDROV, M. BUFALINI, G. GIANNINI, G. CITRO, F. FEROCCE, A. BALDI (*Rome; Viterbo; Naples, Italy; Sofia, Bulgaria*) ..... 47
- Successful Rescue of an Apocrine Gland Carcinoma Metastatic to the Cervical Lymph Nodes by Mitoxantrone Coupled with Trains of Permeabilizing Electrical Pulses (Electrochemotherapy). E.P. SPUGNINI, I. DOTSINSKY, N. MUDROV, A. DE LUCA, C. CODINI, G. CITRO, A. D'AVINO, A. BALDI (*Rome; Naples, Italy; Sofia, Bulgaria*) ..... 51
- Osteopontin Expression in Human Decidua is Associated with Decidual Natural Killer Cells Recruitment and Regulated by Progesterone. X. QU, M. YANG, W. ZHANG, L. LIANG, Y. YANG, Y. ZHANG, B. DENG, W. GAO, J. LIU, Q. YANG, B. KONG, F. GONG (*Wuhan; Jinan, China*) ..... 55
- Curcumin Inhibits WEHI-3 Leukemia Cells in BALB/c Mice *In Vivo*. C.-C. SU, J.-S. YANG, S.-Y. LIN, H.-F. LU, S.-S. LIN, Y.-H. CHANG, W.-W. HUANG, Y.-C. LI, S.-J. CHANG, J.-G. CHUNG (*Hualien; Taichung; Taipei, Taiwan, ROC*) ..... 63
- Inhibitors of Ca<sup>2+</sup> and K<sup>+</sup> Transport Enhance Intracellular Killing of *M. tuberculosis* by Non-killing Macrophages. M. MARTINS, M. VIVEIROS, L. AMARAL (*Lisboa, Portugal*) ..... 69

VCAM-1 Increases Levels of HGF in Eosinophilic Chronic Rhinosinusitis Cell Culture. R. NAIM, T. BRAUN, A. SAUTER, J. BARNES, W. AUST, A. NAUMANN, K. HORMANN, M. BLOCHING ( <i>Homburg/Saar; Mannheim, Germany; Coventry, UK</i> ).....	77
Expression in Childhood Primary Brain Tumors of NY-ESO-1, a Cancer/Testis Antigen: An Immunohistochemical Study. B. BODEY, V. BODEY, S.E. SIEGEL ( <i>Los Angeles, CA, USA</i> ).....	83
Potential Stem Cell Marker CD44 is Constitutively Expressed in Permanent Cell Lines of Head and Neck Cancer. R. PRIES, N. WITTKOPF, T. TRENKLE, S.M. NITSCH, B. WOLLENBERG ( <i>Lübeck, Germany</i> )...	89
Synthesis and Biodistribution Studies of Two Novel Radiolabeled Estrone Derivatives. H. ENGINAR, P. UNAK, F.Y. LAMBRECHT, F.Z. BIBER MUFTULER, E.I. MEDINE ( <i>Afyon; Izmir, Turkey</i> ) .....	93
The Frequency of Lymphocytic Gastritis in Baboons. C.A. RUBIO, E.J. DICK Jr., G.B. HUBBARD ( <i>San Antonio, TX, USA</i> ).....	101
Effects of 4- <i>tert</i> -Octylphenol on the Incubation of Eggs in Japanese Brown Frogs ( <i>Rana japonica</i> ). H. KAWAGUCHI, Y. UMEKITA, M. SOUDA, H. YOSHIDA ( <i>Kagoshima, Japan</i> ).....	105
<i>Clinical Studies</i>	
* <sup>18</sup> F-FDG PET in the Diagnosis and Follow-up of Thyroid Malignancy. A. AL-NAHHAS, S. KHAN, A. GOGBASHIAN, E. BANTI, L. RAMPIN, D. RUBELLO ( <i>London, UK; Rovigo, Italy</i> ) .....	109
Unravelling Intracellular Immune Dysfunctions in Chronic Fatigue Syndrome: Interactions between Protein Kinase R Activity, RNase L Cleavage and Elastase Activity, and their Clinical Relevance. M. MEEUS, J. NIJS, N. MCGREGOR, R. MEEUSEN, G. DE SCHUTTER, S. TRUIJEN, M. FRÉMONT, E. VAN HOOFF, K. DE MEIRLEIR ( <i>Brussels; Antwerp; Zellik, Belgium; Parksville, VIC, Australia</i> ).....	115
Post-coronarography Application of Continuous Venovenous Hemofiltration in the Prevention of Contrast Nephropathy in Patients with Complex Multisystem Deficiency. G. LA MANNA, L. PANCALDI, V. DALMASTRI, V. CUNA, A. CAPECCHI, G. COMAI, E. PERSICI, G. BACCHI, G. CIANCIOLO, A. LOMBARDI, C. MARROZZINI, L. COLÌ, S. STEFONI ( <i>Bologna, Italy</i> ).....	123
Factors Influencing EPA+DHA Levels in Red Blood Cells in Japan. M. ITOMURA, S. FUJIOKA, K. HAMAZAKI, K. KOBAYASHI, T. NAGASAWA, S. SAWAZAKI, Y. KIRIHARA, T. HAMAZAKI ( <i>Toyama; Gifu, Japan</i> ) .....	131
Plasma Glutamate and Glycine Levels in Patients with Amyotrophic Lateral Sclerosis. E. ANDREADOU, E. KAPAKI, P. KOKOTIS, G.P. PARASKEVAS, N. KATSAROS, G. LIBITAKI, O. PETROPOULOU, V. ZIS, C. SFAGOS, D. VASSILOPOULOS ( <i>Athens, Greece</i> ).....	137
Modification of the Harris-Benedict Equation to Predict the Energy Requirements of Critically Ill Patients during Mild Therapeutic Hypothermia. J. SAUR, H. LEWELING, F. TRINKMANN, J. WEISSMANN, M. BORGGREFE, J.J. KADEN ( <i>Mannheim, Germany</i> ) .....	143
Effect of Ala16Val Genetic Polymorphism of <i>MnSOD</i> on Antioxidant Capacity and Inflammatory Response in Open Heart Surgery. S. ISBIR, A. ERGEN, H. YILMAZ, A. TEKELI, S. ARSAN ( <i>Istanbul, Turkey</i> ) .....	147



Multicystic Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). D. BARATTI, S. KUSAMURA, A. SIRONI, A. CABRAS, L. FUMAGALLI, B. LATERZA, M. DERACO ( <i>Milan, Italy</i> ) .....	153
* Review (page 109)	
 <b>Number 2</b>	
<i>Experimental Studies</i>	
Variable Hematopoietic Responses to Acute Photons, Protons and Simulated Solar Particle Event Protons. D.S. GRIDLEY, A. RIZVI, X. LUO-OWEN, A.Y. MAKINDE, G.B. COUTRAKON, P. KOSS, J.M. SLATER, M.J. PECAUT ( <i>Loma Linda, CA, USA</i> ) .....	159
Immunization with a Tissue Vaccine Enhances the Effect of Irradiation on Prostate Tumors. M.A. SUCKOW, J. WHEELER, W.R. WOLTER, V. SAILES, M. YAN ( <i>Notre Dame; Goshen, IN, USA</i> ) .....	171
Studies on the Adaptive Response in Mouse Female Germ Cells X-Irradiated <i>In Vitro</i> at Two Different Stages of Maturation. P. JACQUET, J. BUSET, M. NEEFS, J. VANKERKOM ( <i>Mol, Belgium</i> ) .....	179
Investigation of ABCA1 C69T and G-191C Polymorphisms in Coronary Artery Disease. A. ERGEN, S. ISBIR, A. TEKELI, T. ISBIR ( <i>Istanbul, Turkey</i> ) .....	187
* Estrogen and Progesterone Treatment Mimicking Pregnancy for Protection from Breast Cancer. A. TSUBURA, N. UEHARA, Y. MATSUOKA, K. YOSHIZAWA, T. YURI ( <i>Osaka, Japan</i> ) .....	191
Development of Foreign Body Giant Cells in Response to Implantation of Spongostan® as a Scaffold for Cartilage Tissue Engineering. M. CEGIELSKI, I. IZYKOWSKA, M. PODHORSKA-OKOLOW, M. ZABEL, P. DZIEGIEL ( <i>Wroclaw; Poznan, Poland</i> ) .....	203
Effects of Neonatally Administered Low-dose Diethylstilbestrol on the Induction of Mammary Carcinomas and Dysplasias Induced by 7,12-Dimethylbenz[ <i>a</i> ]anthracene in Female Rats. T. YOSHIKAWA, H. KAWAGUCHI, Y. UMEKITA, M. SOUDA, K. GEJIMA, H. KAWASHIMA, R. NAGATA, H. YOSHIDA ( <i>Kagoshima, Japan</i> ) .....	207
Gypenosides Induced G0/G1 Arrest <i>via</i> Inhibition of Cyclin E and Induction of Apoptosis <i>via</i> Activation of Caspases-3 and -9 in Human Lung Cancer A-549 Cells. H.-F. LU, Y.-S. CHEN, J.-S. YANG, J.-C. CHEN, K.-W. LU, T.-H. CHU, K.-C. LIU, C.-C. YEY, G.-W. CHEN, H.-J. LIN, J.-G. CHUNG ( <i>Taipei; Taichung; Kaohsiung, Taiwan, ROC</i> ) .....	215
Berberine Induced Down-regulation of Matrix Metalloproteinase-1, -2 and -9 in Human Gastric Cancer Cells (SNU-5) <i>In Vitro</i> . J.-P. LIN, J.-S. YANG, C.-C. WU, S.-S. LIN, W.-T. HSIEH, F.-S. YU, C.-S. YU, G.-W. CHEN, Y.-H. CHANG, J.-G. CHUNG ( <i>Taichung; Kaohsiung, Taiwan, ROC</i> ) .....	223
Effect of Bone Mineral with or without Collagen Membrane in Ridge Dehiscence Defects Following Premolar Extraction. M. KIM, J.-H. KIM, J.Y. LEE, K. CHO, S.S. KANG, G. KIM, M.J. LEE, S.H. CHOI ( <i>Cheongju; Yangju; Gwangju; Chunchon, South Korea</i> ) .....	231

The Role of Mitochondria in Bee Venom-induced Apoptosis in Human Breast Cancer MCF7 Cells. S.-W. IP, S.-S. LIAO, S.-Y. LIN, J.-P. LIN, J.-S. YANG, M.-L. LIN, G.-W. CHEN, H.-F. LU, M.-W. LIN, S.-M. HAN, J.-G. CHUNG ( <i>Taichung; Kaohsiung; Taipei, Taiwan, ROC; Suwon, South Korea</i> ).....	237
Recombinant Leptin Administration Improves Early Angiogenesis in Full-thickness Skin Flaps: An Experimental Study. I.E. LIAPAKIS, S. ANAGNOSTOULIS, A. KARAYIANNAKIS, D.P. KORKOLIS, M. LAMBROPOULOU, E. ARNAUD, C.E. SIMOPOULOS ( <i>Athens; Alexandroupolis, Greece; Paris, France</i> ).....	247
<i>Clinical Studies</i>	
Analysis of Cytokine Levels in Human Lymphangiomas. S. WIEGAND, B. EIVAZI, S. SEL, H. RENZ, J.A. WERNER, B.J. FOLZ ( <i>Marburg; Bad Lippspringe, Germany</i> ) .....	253
Efficacy of Cancer Chemotherapy in Relation to Synchronization of Cortisol Rhythm, Immune Status and Psychospiritual Profile in Metastatic Non-small Cell Lung Cancer. P. LISSONI, G. MESSINA, A. BALESTRA, M. COLCIAGO, F. BRIVIO, L. FUMAGALLI, G. FUMAGALLI, D. PAROLINI ( <i>Monza; Milan, Italy</i> ).....	257
* Control of Interstitial Pneumonia by Drip Infusion of Megadose Vitamin C, Dehydroepiandrosterone and Cortisol. A Short Review of our Experience. M. KODAMA, A. OYAMA, H. TAKAGI ( <i>Nagoya, Japan</i> ).....	263
Chronic Cholecystitis in Elderly Patients. Correlation of the Severity of Inflammation with the Number and Size of the Stones. P.J. DOMEYER, T.N. SERGENTANIS, F. ZAGOURI, B. TZILALIS, E. MOUZAKIOTI, A. PARASI, A. NONNI, A. MARIOLIS, G. ANDROULAKIS, G.C. ZOGRAFOS ( <i>Athens, Greece</i> ) .....	269
* Reviews (pages 191, 263)	
<b>Number 3</b>	
<b>Special Issue on New Anticancer Agents</b>	
* New Chemotherapy Strategies for Gastric Cancer. T. KUBOTA ( <i>Tokyo, Japan</i> ).....	273
Role of Transporter Genes in Cisplatin Resistance. V.B. KONKIMALLA, B. KAINA, T. EFFERTH ( <i>Heidelberg; Mainz, Germany</i> ) .....	279
NLNQ-1, a 2-[3-(2-Nitro-1-Imidazolyl) Propylamino]-3-Chloro-1,4-Naphthoquinone, as a Hypoxia-selective Cytotoxin and Radiosensitizer. M.V. PAPADOPOULOU, W.D. BLOOMER ( <i>Evanston, IL, USA</i> ) .....	285
Comparative Study of the Alkyl and Peroxy Radical-scavenging Activity of 2- <i>t</i> -Butyl-4-methoxyphenol (BHA) and its Dimer, and their Theoretical Parameters. Y. KADOMA, S. ITO, I. YOKOE, S. FUJISAWA ( <i>Tokyo; Saitama, Japan</i> ) .....	289
Methylene Blue in Place of Acridine Orange as a Photosensitizer in Photodynamic Therapy of Osteosarcoma. T. MATSUBARA, K. KUSUZAKI, A. MATSUMINE, H. SATONAKA, K. SHINTANI, T. NAKAMURA, A. UCHIDA ( <i>Tsu; Taki; Mie, Japan</i> ).....	297

* $\gamma$ -H2AX – A Novel Biomarker for DNA Double-strand Breaks. L.J. KUO, L.-X. YANG ( <i>San Francisco, CA, USA</i> ) .....	305
* Heat Shock Proteins as Novel Therapeutic Targets in Cancer. E.T.L. SOO, G.W.C. YIP, Z.M. LWIN, S.D. KUMAR, B.-H. BAY ( <i>Singapore, Singapore</i> ) .....	311
Induction of Differentiation in Human Promyelocytic Cells by the Isothiocyanate Sulforaphane. C. FIMOGNARI, M. LENZI, G. CANTELLI-FORTI, P. HRELIA ( <i>Bologna, Italy</i> ).....	317
Target Specificity of <sup>188</sup> Re-labeled B27.1 Monoclonal Antibodies to Ovarian Cancer Cells <i>In Vivo</i> . S. PALAKURTHI, J. WILSON, S.A. McQUARRIE, M.R. SURESH, J.R. MERCER, G.G. MILLER ( <i>Brookings, SD, USA; Edmonton, AB, Canada</i> ) .....	321
Anti-HIV and Vitamin C-synergized Radical Scavenging Activity of Cacao Husk Lignin Fractions. H. SAKAGAMI, K. SATOH, H. FUKAMACHI, T. IKARASHI, A. SHIMIZU, K. YANO, T. KANAMOTO, S. TERAUBO, H. NAKASHIMA, H. HASEGAWA, A. NOMURA, K. UTSUMI, M. YAMAMOTO, Y. MAEDA, K. OSAWA ( <i>Saitama; Tokyo; Kanagawa, Japan</i> ) .....	327
COX-2 as Possible Target for the Inhibition of PGE <sub>2</sub> Production by <i>Rikko-san</i> in Activated Macrophage. N. HORIE, K. HASHIMOTO, T. KATO, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI ( <i>Saitama; Tokyo, Japan</i> ) .....	333
Prevention of Lethal Tumor Growth and Generation of Long-lasting Immunity <i>In Vivo</i> Using CD137L and Interleukin-12 Gene Transfer. Y. KIM, J.W. STREHL, M. GORSCHLÜTER, C. ZISKE, I.G.H. SCHMIDT-WOLF ( <i>Bonn, Germany</i> ).....	337
Synthesis, <i>In Vivo</i> Antileukemic Evaluation and Comparative Study of Novel 5 $\alpha$ -7-Keto Steroidal Esters of Chlorambucil and its Active Metabolite. A.I. KOUTSOUREA, M.A. FOUSTERIS, E.S. ARSENOU, A. PAPAGEORGIOU, G.N. PAIRAS, S.S. NIKOLAROPOULOS ( <i>Patras; Thessaloniki, Greece</i> ).....	345
Inhibitory Effect of Nordihydroguaiaretic Acid and its Tetra-acetylated Derivative on Respiration and Growth of Adenocarcinoma TA3 and its Multiresistant Variant TA3MTX-R. C. PLAZA, M. PAVANI, M. FAUNDEZ, J.D. MAYA, A. MORELLO, M.I. BECKER, A. DE IOANNES, M.A. CUMSILLE, J. FERREIRA ( <i>Santiago, Chile</i> ).....	353
Juice of <i>Eclipta prostrata</i> Inhibits Cell Migration <i>In Vitro</i> and Exhibits Anti-angiogenic Activity <i>In Vivo</i> . K. LIRDPRAPAMONGKOL, J.-P. KRAMB, D. CHOKCHAICHAMNANKIT, C. SRISOMSAP, R. SURARIT, M. SILA-ASNA, A. BUNYARATVEJ, G. DANNHARDT, J. SVASTI ( <i>Bangkok; Nakornpathom, Thailand; Mainz, Germany</i> ) .....	363
Ethanol Extract of <i>Dunaliella salina</i> Induces Cell Cycle Arrest and Apoptosis in A549 Human Non-small Cell Lung Cancer Cells. M.-J. SHEU, G.-J. HUANG, C.-H. WU, J.-S. CHEN, H.-Y. CHANG, S.-J. CHANG, J.-G. CHUNG ( <i>Taichung city; Wufeng, Taichung County, Taiwan, ROC</i> ).....	369
MDR-reversal Activity of Chalcones. A. IVANOVA, D. BATOVSKA, H. ENGI, S. PARUSHEV, I. OCSOVSKI, I. KOSTOVA, J. MOLNAR ( <i>Sofia, Bulgaria; Szeged, Hungary</i> ).....	379
* The Biological Role of Chondroitin Sulfate in Cancer and Chondroitin-based Anticancer Agents. A.P. ASIMAKOPOULOU, A.D. THEOCHARIS, G.N. TZANAKAKIS, N.K. KARAMANOS ( <i>Patras; Heraklion, Greece</i> ) .....	385

Effects of Morin on the Bioavailability of Tamoxifen and its Main Metabolite, 4-Hydroxytamoxifen, in Rats. S.-C. SHIN, Y.-J. PIAO, J.-S. CHOI ( <i>Gwangju, South Korea</i> ).....	391
A Study of Immunoendocrine Strategies with Pineal Indoles and Interleukin-2 to Prevent Radiotherapy-induced Lymphocytopenia in Cancer Patients. P. LISSONI, F. ROVELLI, F. BRIVIO, L. FUMAGALLI, G. BRERA ( <i>Monza; Milan, Italy</i> ).....	397
Errata.....	401
* Reviews (pages 273, 305, 311, 385)	

## Number 4

### *Experimental Studies*

Characterization of a New Rat Model of Head and Neck Squamous Cell Carcinoma. K. AUBRY, F. PARAF, J. MONTEIL, J.P. BESSEDE, M. RIGAUD ( <i>Limoges, France</i> ).....	403
Alteration of Inflammatory Cytokine Production in the Injured Central Nervous System of Tenascin-deficient Mice. H. IKESHIMA-KATAOKA, J.-S. SHEN, Y. ETO, S. SAITO, S. YUASA ( <i>Tokyo, Japan</i> ).....	409
Regulation of Matrix Metalloproteinases (MMP)-2/-9 Expression in Eosinophilic Chronic Rhinosinusitis – Cell Culture by Interleukin-5 and -13 ? A. SAUTER, J. STERN-STRAETER, S. SODHA, K. HÖRMANN, R. NAIM ( <i>Mannheim; Homburg/Saar, Germany; Coventry, UK</i> ) .....	415
Radiation and Secondary Immune Response to Lipopolysaccharide. M.J. PECAUT, D.S. GRIDLEY ( <i>Loma Linda, CA, USA</i> ).....	423
Corticosterone Concentrations in Blood and Excretion in Faeces after ACTH Administration in Male Sprague-Dawley Rats. H. SISWANTO, J. HAU, H.-E. CARLSSON, R. GOLDKUHL, K.S.P. ABELSON ( <i>Uppsala, Sweden; Copenhagen, Denmark</i> ) .....	435
* Indole-3-carbinol as a Chemoprotective Agent in Breast and Prostate Cancer. H.L. BRADLOW ( <i>Hackensack; Newark, NJ, USA</i> ).....	441
Progestational Agents Prevent Preterm Birth Induced by a Nitric Oxide Synthesis Inhibitor in the Mouse. G.M. TIBONI, A. DEL CORSO, F. MAROTTA ( <i>Chieti, Italy</i> ) .....	447
10 Years' Experience in Fragile X Testing Among Mentally Retarded Individuals in Greece: A Molecular and Epidemiological Approach. C. SOFOCLEOUS, S. KITSIOU, H. FRYSSIRA, A. KOLIALEXI, M. KALAITZIDAKI, E. ROMA, G.T. TSANGARIS, C. CHISTOFIDOU, C. METAXOTOU, E. KANAVAKIS, A. MAVROU ( <i>Athens, Greece</i> ).....	451
Possible Relation Between Histone 3 and Cytokeratin 18 in Human Hepatocellular Carcinoma. C.-C. HO, C.-C. CHENG, Y.-H. LIU, R.-J. PEI, Y.-H. HSU, K.-T. YEH, L.-C. HO, M.-C. TSAI, Y.-S. LAI ( <i>Taichung; Hualien; Changhua, Taiwan, ROC</i> ).....	457
Expression of Extracellular Matrix Metalloproteinase (MMP-9), E-Cadherin and Proliferation-associated Antigen Ki-67 and their Reciprocal Correlation in Canine Mammary Adenocarcinomas. M. NOWAK, J.A. MADEJ, M. PODHORSKA-OKOLOW, P. DZIEGIEL ( <i>Wroclaw, Poland</i> ) .....	463

Antiviral, Antibacterial and Vitamin C-synergized Radical-scavenging Activity of <i>Sasa senanensis</i> Rehder Extract. H. SAKAGAMI, S. AMANO, H. KIKUCHI, Y. NAKAMURA, R. KUROSHITA, S. WATANABE, K. SATOH, H. HASEGAWA, A. NOMURA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, S. TANIGUCHI, T. OIZUMI ( <i>Saitama; Tokyo; Kanagawa, Japan</i> ) .....	471
<i>APE1</i> and <i>XRCC3</i> Polymorphisms and Myocardial Infarction. A. TEKELI, S. İSBİR, A. ERGEN, U. GÖRMÜŞ, N. BOZKURT, Ö. TIMIRCI, S. ARSAN, T. İSBİR ( <i>Istanbul, Turkey</i> ) .....	477
<i>Clinical Studies</i>	
* Interleukin-2 Inhalation Therapy in Renal Cell Cancer: A Case Report and Review of the Literature. G. DEL MONTE, P. FERRONI, S. MARIOTTI, E. FOSSILE, F. GUADAGNI, M. ROSELLI ( <i>Rome, Italy</i> ) .....	481
A Color Doppler Ultrasound-based Comparative Study between Stavudine and Non-stavudine Regimens in the Onset of Vascular Lesions in HIV-1-positive Patients. P. MAGGI, A. CHIRIANNI, A. LILLO, F. PERILLI, M. GARGIULO, V. ESPOSITO, C. BELLACOSA, G. PASTORE, G. REGINA ( <i>Bari; Napoli, Italy</i> ) .....	489
* Non-papillary Urothelial Lesions of the Urinary Bladder: Morphological Classification and Immunohistochemical Markers. C.D. PETRAKI, C.P. SFIKAS ( <i>Athens, Greece</i> ) .....	493
Skin Grafting: Comparative Evaluation of Two Dressing Techniques in Selected Body Areas. F. DE GADO, S. CHIUMMARIELLO, C. MONARCA, L.A. DESSY, M.I. RIZZO, C. ALFANO, N. SCUDERI ( <i>Rome; Perugia, Italy</i> ) .....	503
Postmeal Portal Flow Variations in HCV-related Chronic Hepatitis and Liver Cirrhosis with and without Hyperdynamic Syndrome. E.M. ZARDI, A. DOBRINA, V. UWECHIE, F. CACCIAPAGLIA, M. ROLLO, V. LAGHI, G. AMBROSINO, F. LUMACHI ( <i>Trieste; Rome; Padova, Italy</i> ) .....	509
<sup>18</sup> F-FDG PET/CT in Myeloma with Presumed Solitary Plasmocytoma of Bone. C. NANNI, D. RUBELLO, E. ZAMAGNI, P. CASTELLUCCI, V. AMBROSINI, G. MONTINI, M. CAVO, F. LODI, C. PETTINATO, G. GRASSETTO, R. FRANCHI, M.D. GROSS, S. FANTI ( <i>Bologna; Rovigo, Italy; Ann Arbor, MI, USA</i> ) .....	513
Ultrastructural Changes in Regressing Equine Sarcoid Tumours – Mysterious Role of Mitochondria. R.E. HALLAMAA ( <i>Helsinki, Finland</i> ) .....	519
Malondialdehyde and Protein Carbonyl as Biomarkers for Oxidative Stress and Disease Progression in Patients with Chronic Myeloid Leukemia. R. AHMAD, A.K. TRIPATHI, P. TRIPATHI, S. SINGH, R. SINGH, R.K. SINGH ( <i>Lucknow, India</i> ) .....	525
* EGFR Mutations in Non-small Cell Lung Cancer – Clinical Implications. A. CHARPIDOU, D. BLATZA, E. ANAGNOSTOU, K.N. SYRIGOS ( <i>Athens, Greece</i> ) .....	529
Apolipoprotein J and Leptin Levels in Patients with Coronary Heart Disease. M.V. POULAKOU, K.I. PARASKEVAS, M.R. WILSON, D.C. ILIOPOULOS, C. TSIGRIS, D.P. MIKHAILIDIS, D. PERREA ( <i>Athens, Greece; London, UK; Wollongong, NSW, Australia</i> ) .....	537
* Reviews (pages 441, 481, 493, 529)	

**Number 5**

*Experimental Studies*

Degradation of Plectin with Modulation of Cytokeratin 18 in Human Liver Cells during Staurosporine-induced Apoptosis. Y.-H. LIU, C.-C. CHENG, C.-C. HO, W.-T. CHAO, R.-J. PEI, Y.-H. HSU, K.-T. YEH, L.-C. HO, M.-C. TSAI, Y.-S. LAI (*Taichung; Hualien; Changhua, Taiwan; Houston, TX, USA*)..... 543

*In Vitro* Study of Interleukin-5 (IL-5) in Human Eosinophilic Chronic Rhinosinusitis Cell Culture. A. SAUTER, J. BARNES, J. STERN-STRAETER, K. HÖRMANN, R. NAIM (*Mannheim; Homburg/Saar; Germany; Coventry, UK*) ..... 549

A Tobacco-specific Carcinogen, NNK, Enhances AOM/DSS-induced Colon Carcinogenesis in Male A/J Mice. M. KIM, S. MIYAMOTO, S. SUGIE, Y. YASUI, R. ISHIGAMORI-SUZUKI, A. MURAKAMI, H. NAKAGAMA, T. TANAKA (*Ishikawa; Kyoto; Tokyo, Japan*)..... 557

Frequency of the Cancer-resistant Phenotype in SR/CR Mice and the Effect of Litter Seriation. J. KOCH, A. BOSCHIAN, J. HAU, K. RIENECK (*Copenhagen; Denmark*)..... 565

Effect of Sairei-to and its Ingredients on Prostaglandin Production by Mouse Macrophage-like Cells E<sub>2</sub>. T. KANEKO, H. CHIBA, N. HORIE, T. KATO, K. HASHIMOTO, K. KUSAMA, H. SAKAGAMI (*Tokyo; Saitama, Japan*)..... 571

A Spiritual Approach in the Treatment of Cancer: Relation between Faith Score and Response to Chemotherapy in Advanced Non-small Cell Lung Cancer Patients. P. LISSONI, G. MESSINA, D. PAROLINI, A. BALESTRA, F. BRIVIO, L. FUMAGALLI, L. VIGORE, F. ROVELLI (*Monza, Milan, Italy*)..... 577

Bimodal Effect of Glycyrrhizin on Macrophage Nitric Oxide and Prostaglandin E<sub>2</sub> Production. T. KATO, N. HORIE, K. HASHIMOTO, K. SATOH, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama, Tokyo, Japan*) ..... 583

Erythropoietin and Growth Factors Exhibit Differential Angiogenic Potential in Mouse Heart. O. PAGONOPOULOU, A. EFTHIMIADOU, M. LAMBROPOULOU, N. PAPADOPOULOS, N.K. NIKOLETTOS (*Alexandroupolis, Greece*)..... 587

A High Concentration of MMP-2/Gelatinase A and MMP-9/Gelatinase B Reduce NK Cell-mediated Cytotoxicity against an Oral Squamous Cell Carcinoma Cell Line. B.-K. LEE, M.-J. KIM, H.-S. JANG, H.-R. LEE, K.-M. AHN, J.-H. LEE, P.-H. CHOUNG, M.-J. KIM (*Seoul, South Korea*) ..... 593

HPV Detection Rate in Saliva May Depend on the Immune System Efficiency. M. ADAMOPOULOU, E. VAIRAKTARIS, V. PANIS, E. NKENKE, F.W. NEUKAM, C. YAPIJAKIS (*Athens, Greece; Nürnberg, Germany*)..... 599

Hypothyroidism and the Aorta. Evidence of Increased Oxidative DNA Damage on the Aorta of Hypothyroid Rats. K.G. MOULAKAKIS, M.V. POULAKOU, T. DOSIOS, I. DONTAS, D.P. SOKOLIS, I.S. VLACHOS, M.C. SAFIOLEAS, P. PAPACHRISTODOULOU, P.E. KARAYANNACOS. D.N. PERREA (*Athens, Greece*) ..... 603

*Clinical Studies*

Serum Lipid Profile and Plasma Fatty Acid Composition in Hemodialysis Patients – Comparison with Chronic Kidney Disease Patients. N. NAKAMURA, T. FUJITA, R. KUMASAKA, R. MURAKAMI, M. SHIMADA, Y. SHIMAYA, H. OSAWA, H. YAMABE, K. OKUMURA (*Aomori, Japan*)..... 609

Incidence of Lymphocytic Esophagitis in Baboons. C.A. RUBIO, E.J. DICK JR, A. ORREGO, G.B. HUBBARD (*San Antonio, TX, USA*) ..... 613

Menstrual Problems in University Students: An Electronic Mail Survey. E. ANASTASAKIS, C.E. KINGMAN, C.A. LEE, D.L. ECONOMIDES, R.A. KADIR (*London, UK*) ..... 617

H-Ras and c-Fos Exhibit Similar Expression Patterns During Most Stages of Oral Oncogenesis. E. VAIRAKTARIS, V. PAPAKOSTA, S. DERKA, S. VASSILIOU, E. NKENKE, S. SPYRIDONIDOU, A. VYLLIOTIS, A. LAZARIS, A. KOKKORI, P. MOULAVASSILI, S. LOUKERI, D. PERREA, I. DONTA, C. YAPIJAKIS, E. PATSOURIS (*Athens, Greece; Nürnberg, Germany*) ..... 621

Short-term Safety and Curative Effect of Recombinant Adenovirus Carrying *Hepatocyte Growth Factor* Gene on Ischemic Cardiac Disease. B. YUAN, Z. ZHAO, Y.-R. ZHANG, C.-T. WU, W.-G. JIN, S. ZHAO, W. WANG, Y.-Y. ZHANG, X.-L. ZHU, LI-S. WANG, J. HUANG (*Beijing, China*)..... 629

\* Osteochondromas: Review of the Clinical, Radiological and Pathological Features. P. KITSOULIS, V. GALANI, K. STEFANAKI, G. PARASKEVAS, G. KARATZIAS, N.J. AGNANTIS, M. BAI (*Ioannina; Athens; Thessaloniki, Greece*) ..... 633

T-Helper / T-Regulator Lymphocyte Ratio as a New Immunobiological Index to Quantify the Anticancer Immune Status in Cancer Patients. F. BRIVIO, L. FUMAGALLI, D. PAROLINI, G. MESSINA, F. ROVELLI, R. RESCALDANI, L. VIGORE, R. VEZZO, M. VAGHI, S. DI BELLA, P. LISSONI (*Monza, Milan, Italy*)..... 647

Congenital Cholesteatoma Extending into the Internal Auditory Canal and Cochlea: A Case Report. C.H. JANG, Y.B. CHO (*Gwangju, South Korea*) ..... 651

\* Review (page 633)

**Number 6**

*Experimental Studies*

Effects of Lipopolysaccharide Endotoxin on the Insulin-like Growth Factor I System in Rats with Cirrhosis. K.L. THOMSEN, S.S. NIELSEN, H. GRØNBÆK, A. FLYVBJERG, H. VILSTRUP (*Aarhus, Denmark*) ... 655

The Frequency of Gastric Amyloidosis in Baboons. A 22-year Survey at a Large Primate Facility. C.A. RUBIO, E.J. DICK Jr., G.B. HUBBARD (*San Antonio, TX, USA*) ..... 663

Development and Validation of a Multi-dose Neutropenic Rat Thigh Infection Model Using Real-time Monitoring of *Staphylococcus aureus* Growth *In Vivo*. H. ZHANG, G. KALKERI, N. MANI, T.H. GROSSMAN (*Cambridge, MA, USA*)..... 667

Nitric Oxide Effects on the Function of Aged Cells *Ex Vivo* and *In Vivo*. M.J. REED, D. EYMAN, N. KARRES (*Seattle, WA, USA*)..... 673

Further Studies on Long-term Preservation of Rat Liver: Celsior versus UW Solution. A. FERRIGNO, A. TARTAGLIA, A. DI NUCCI, V. BERTONE, P. RICHELMI, D. NERI, I. FREITAS, M. VAIRETTI ( <i>Pavia; Padua, Italy</i> ) .....	681
Modulation of Eosinophil Survival by Epinastine Hydrochloride, an H <sub>1</sub> Receptor Antagonist, <i>In Vitro</i> . F. WATASE, S. WATANABE, K.-I. KANAI, N. YAMADA, S. SAKAUE, K. ASANO, T. HISAMITSU, H. SUZAKI ( <i>Tokyo, Japan</i> ).....	687
Biodistribution and Pharmacokinetics of Transgenic Pigproduced Recombinant Human Factor IX (rhFIX) in Rats. C.-H. CHANG, T.-K. CHOU, C.-Y. YANG, T.-J. CHANG, Y.-H. WU, T.-W. LEE ( <i>Taoyuan; Miaoli, Taiwan, ROC</i> ).....	693
Effects of Neonatal Administration of Diethylstilbestrol on Aberrant Crypt Foci Induced by 7,12-Dimethylbenz[ <i>a</i> ]anthracene in Rats. H. KAWASHIMA, H. KAWAGUCHI, Y. UMEKITA, M. SOUDA, K. GEJIMA, T. KOMOKATA, R. SAKATA, H. YOSHIDA ( <i>Kagoshima, Japan</i> ).....	699
The Effect of Chemotherapy against Micrometastases and Isolated Tumor Cells in Lymph Nodes: An <i>In Vivo</i> Study. T. EGUCHI, Y. KODERA, H. NAKANISHI, H. YOKOYAMA, N. OHASHI, Y. ITO, G. NAKAYAMA, M. KOIKE, M. FUJIWARA, A. NAKAO ( <i>Nagoya, Japan</i> ).....	707
Aberrant Activation of Interleukin-9 Receptor and Downstream Stat3/5 in Primary T-cell Lymphomas <i>In Vivo</i> in Susceptible B6 and Resistant C3H Mice. Y. SHANG, S. KAKINUMA, Y. AMASAKI, M. NISHIMURA, Y. KOBAYASHI, Y. SHIMADA ( <i>Funabashi; Chiba, Japan</i> ).....	713
The Frequency of Histological Features Mimicking Reflux Esophagitis: A Study in Non-human Primates. C.A. RUBIO, E.J. DICK Jr., L. FORSELL, G.B. HUBBARD ( <i>San Antonio, TX, USA</i> ).....	721
The Prevalence of Colonic Amyloidosis in Baboons. A 22-year Survey at a Large Primate Facility. C.A. RUBIO, E.J. DICK Jr., G.B. HUBBARD ( <i>San Antonio, TX, USA</i> ).....	725
Effects of Luteolin by Oral Administration on Distribution and Metabolism of 2-Aminofluorene in Male Sprague-Dawley Rats. M.-D. YANG, S.-Y. LIN, T.-H. CHIU, C.-C. LIN, M.-L. LIN, S.-C. HSU, C.-L. KUO, M.-J. SHEU, C.-C. WU, S.-S. LIN, J.-G. CHUNG ( <i>Taichung; Fong Yuan; Kaohsiung, Taiwan, ROC</i> ).....	729
* The Role of Urokinase-type Plasminogen Activator (uPA) and Transforming Growth Factor Beta 1 (TGFβ1) in Muscle Regeneration. A. PHILIPPOU, M. MARIDAKI, M. KOUTSILIERIS ( <i>Athens, Greece</i> ) .....	735
Electrochemotherapy-induced Radiation Recall in a Cat. E.P. SPUGNINI, I. DOTSINSKY, N. MUDROV, G. CITRO, G. CARUSO, P. CARDELLI, A. BALDI ( <i>Rome; Naples, Italy; Sofia, Bulgaria</i> ) .....	751
Prostate as Sole Unusual Recurrence Site of Lymphoma in a Dog. R. ASSIN, A. BALDI, G. CITRO, E.P. SPUGNINI ( <i>Rome; Naples, Italy</i> ).....	755
Adjuvant Carboplatin for the Treatment of Intestinal Carcinoid in a Dog. E.P. SPUGNINI, M. GARGIULO, R. ASSIN, A. D'AVINO, P. MELLONE, G. CITRO, P. CARDELLI, A. BALDI ( <i>Rome; Naples, Italy</i> ).....	759



Antibacterial Effect of Octylcyanoacrylate against Methicillin-resistant <i>Staphylococcus aureus</i> Isolates from Patients with Chronic Suppurative Otitis Media. C.H. JANG, H. PARK, C.H. CHOI, Y.B. CHO, I.Y. PARK ( <i>Gwangju; Cheonan, South Korea</i> ).....	763
* <i>In Vivo</i> Models For Heart Failure Research. A. HALAPAS, A. PAPALOIS, A. STAUROPOULOU, A. PHILIPPOU, N. PISSIMISSIS, A. CHATZIGEORGIOU, E. KAMPER, M. KOUTSILIERIS ( <i>Athens, Greece</i> ) .....	767
Effects of Curcumin on <i>N-bis</i> (2-Hydroxypropyl)nitrosamine (DHPN)-induced Lung and Liver Tumorigenesis in BALB/c Mice <i>In Vivo</i> . A.-C. HUANG, S.-Y. LIN, C.-C. SU, S.-S. LIN, C.-C. HO, T.-C. HSIA, T.-H. CHIU, C.-S. YU, S.-W. IP, T.-P. LIN, J.-G. CHUNG ( <i>Yuanlin, Changhua; Hualien; Taichung; Wufeng, Taiwan, ROC</i> ) .....	781
Inhibition of Human Cytomegalovirus IE Gene Expression by Dihydro- $\beta$ -agarofuran Sesquiterpenes Isolated from <i>Euonymus</i> Species. R. PUSZTAI, J. HOHMANN, D. RÉDEI, H. ENGI, J. MOLNÁR ( <i>Szeged, Hungary</i> ) .....	787
Early Modification of <i>c-myc</i> , <i>Ha-ras</i> and <i>p53</i> Expressions by <i>N</i> -Methyl- <i>N</i> -nitrosourea. F. BUDÁN, T. VARJAS, G. NOWRASTEH, Z. VARGA, I. BONCZ, J. CSEH, I. PRANTNER, T. ANTAL, E. PÁZSIT, G. GÓBEL, M. BAUER, T. GRACZA, P. PERJÉSI, I. EMBER, Z. GYÖNGYI ( <i>Pécs; Székesfehérvár; Miskolc, Hungary</i> ).....	793
<i>Clinical Studies</i>	
Validation of the Energy Index Point Score to Serially Measure the Degree of Disability in Patients with Chronic Fatigue Syndrome. A.M. LERNER, S.H. BEQAJ, J.T. FITZGERALD ( <i>Royal Oak; Ann Arbor, MI; Indianapolis, IN, USA</i> ) .....	799
Salvage Surgery for Locoregional Failure after Definitive Radiotherapy for Base of Tongue Cancer. M. KÁSLER, J. FODOR, F. OBERNA, T. MAJOR, C. POLGÁR, Z. TAKÁCSI-NAGY ( <i>Budapest; Kecskemét, Hungary</i> ) .....	803
Late Liver Metastases of Choroidal Melanoma Detected by Laparoscopy. R. ORLANDO, F. LUMACHI ( <i>Padova, Italy</i> ).....	807
Umbilical Endometriosis, Our Experience. L.A. DESSY, E.M. BUCCHERI, S. CHIUMMARIELLO, D.N. GAGLIARDI, M.G. ONESTI ( <i>Rome; Perugia, Italy</i> ).....	811
Inflammatory Pseudotumor of the Hypopharynx: Clinical Diagnosis, Immunohistochemical Findings and Treatment of this Rare Disease. H. GRAEFE, F. STELLMACHER, K. SOTLAR, B. WOLLENBERG, E. GEHRKING ( <i>Lübeck; Munich, Germany</i> ) .....	817
Recurrent Atypical Eccrine Spiradenoma of the Forehead. S. DELFINO, V. TOTO, B. BRUNETTI, A. BIANCHI, A. BALDI, P. PERSICHETTI ( <i>Rome; Naples, Italy</i> ) .....	821
Systemic Sclerosis Associated with Rectal Cancer. Case Report and a Brief Review of the Literature. G. ORPHANOS, A. ARDAVANIS, P. CHARALAMBOUS, J. STAVRAKAKIS, G. RIGATOS ( <i>Athens, Greece; Nicosia, Cyprus</i> ).....	825

Low-dose Oral Metronomic Chemotherapy Prevents Mobilization of Endothelial Progenitor Cells into the Blood of Cancer Patients. S. STOELTING, T. TREFZER, J. KISRO, A. STEINKE, T. WAGNER, S.O. PETERS ( <i>Luebeck, Germany</i> ).....	831
DNA Aneuploidy Study for Early Detection of Chromosomal Abnormality in Patients with Aplastic Anemia: Prognostic and Therapeutic Implications. P. TRIPATHI, A.K. TRIPATHI, A. KUMAR, R. AHMAD, A.K. BALAPURE, A.L. VISHWAKERMA, R.K. SINGH ( <i>Lucknow, India</i> ).....	837
A Study of Surgical Psychoncology in Breast Cancer: Perioperative Variation of Prolactin Serum Levels in Women with Operable Breast Cancer in Relation to their Maternal Psychological Behaviour. G. MESSINA, P. LISSONI, F. BRIVIO, F. ROVELLI, L. FUMAGALLI, E. BARTOLACELLI, U. MAZZA, E. COLOMBO, A. BERTOGLIO ( <i>Milan, Italy</i> ).....	845
Index.....	849

\* Review (page 735, 767)

## Subject Index

(Figures refer to page numbers)

- A549, *Dunaliella salina*,  $\beta$ -carotene, apoptosis, *p53*, NSCLS, 369
- ABC transporter, cisplatin, copper transporter, drug resistance, microarray, pharmacogenomics, 279
- ABCA1, lipoproteins, coronary artery disease, genetic, polymorphism, VLDL, cholesterol, 187
- Aberrant crypt foci (ACF), colon cancer, digestive system, diethylstilbestrol (DES), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), rat, 699
- Abortion, osteopontin, pregnancy, natural killer cells, progesterone, 55
- Acridine orange, methylene blue, photodynamic therapy, osteosarcoma, 297
- ACTH, non-invasive stress assessment, corticosterone, rats, 435
- Adaptive response, oocytes, follicle culture, ionizing radiation, chromosome aberrations, 179
- Adenocarcinomas, MMP-9, E-cadherin, Ki-67 protein, dog, 463
- Adjuvant therapy, gastric cancer, advanced and recurrent, new drugs, review, 273
- 2-AF metabolites, luteolin, *N*-acetyltransferase (NAT), 2-aminofluorene (2-AF), *N*-acetyl-2-aminofluorene (2-AAF), 729
- Age, fish intake, gender, Omega-3 Index, physical activity, 131
- Aged, mice, endothelial cells, nitric oxide, aortic rings, angiogenesis, wound repair, 673
- Allograft, rat model, head and neck squamous cell carcinoma, FDG-PET/CT, 403
- 17-Allyl-17-dimethoxygeldanamycin, heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP 90, HSP inhibitors, geldamycin, review, 311
- Alveolar ridge defects, computed tomography, bone mineral, collagen membrane, dogs, 231
- 2-Aminofluorene (2-AF), luteolin, *N*-acetyltransferase (NAT), *N*-acetyl-2-aminofluorene (2-AAF), 2-AF metabolites, 729
- Amyloidosis, colon, baboon, 725
- Amyloidosis, stomach, baboons, 663
- Amyotrophic lateral sclerosis, glutamate, glycine, excitotoxicity, plasma, 137
- Anatomical distribution, eccrine spiradenoma, histopathological subtype, 821
- Angiogenesis, aged, mice, endothelial cells, nitric oxide, aortic rings, wound repair, 673
- Angiogenesis, erythropoietin, growth factors, mouse heart, 587
- Angiogenesis, leptin, surgical flaps, survival rate, ischaemia, wound healing, 247
- Animal model, heart failure, cardiac remodelling, review, 767
- Anti-angiogenic, anti-metastatic, cell migration, medicinal plants, 363
- Antibacterial activity, SE, lignin, radical-scavenging activity, anti-HIV activity, vitamin C, 471
- Antibacterial effect, octylcyanoacrylate, methicillin-resistant *Staphylococcus aureus*, methicillin-sensitive *Staphylococcus aureus*, otorrhea, 763
- Anticancer agents, heat shock proteins (HSPs), molecular chaperones, HSP 90, HSP inhibitors, geldamycin, 17-allyl-17-dimethoxygeldanamycin, review, 311
- Anticancer immunity, immunosuppression, lymphocytes, T-regulator lymphocytes, 647
- Antigen retrieval, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, 83
- Anti-HIV activity, cacao husk lignin, radical scavenging activity, vitamin C, 327
- Anti-HIV activity, SE, lignin, radical-scavenging activity, antibacterial activity, vitamin C, 471
- Antileukemic activity, chlorambucil, 7-keto-steroids, SAR, steroidal esters, catalytic reduction, 345
- Anti-metastatic, anti-angiogenic, cell migration, medicinal plants, 363
- Antitumor promotion, *Euonymus* species, dihydro- $\beta$ -agarofuran, sesquiterpene, cytomegalovirus, IE antigen expression, 787
- Aorta, hypothyroidism, 8-oxod-G, oxidative stress, 603
- Aortic rings, aged, mice, endothelial cells, nitric oxide, angiogenesis, wound repair, 673
- Aplastic anemia, DNA aneuploidy, flow cytometry, prognosis, chromosomal abnormality, 837
- Apolipoprotein J, atherosclerosis, coronary artery disease, clusterin, leptin, 537
- Apoptosis, 2-methoxyestradiol, rat osteosarcoma, rat malignant fibrous histiocytoma, 21
- Apoptosis, bee venom (BV), MCF7 cells, caspase, ROS, mitochondria, 237
- Apoptosis, cytokeratin, plectin, hepatocellular carcinoma, staurosporine, 543
- Apoptosis, *Dunaliella salina*,  $\beta$ -carotene, A549, *p53*, NSCLS, 369
- Apoptosis, gypenosides, caspase-3, Bcl-2, Bax, *p53*, cell cycle, 215
- Apoptosis, sulforaphane, cytodifferentiation, granulocytes, macrophages, HL-60 cells, 317

- ASTR, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Astrocytes, central nervous system (CNS), glial fibrillary acidic protein (GFAP), lesion, tenascin-C (TN), 409
- Atelexis albiventris*, lymphoma, skin, surgery, T-cell, 43
- Atherosclerosis, coronary artery disease, apolipoprotein J, clusterin, leptin, 537
- Atherosclerosis, stavudine, protease inhibitors, color Doppler ultrasonography, carotid, HIV, 489
- ATP level, nordihydroguaiaretic acid derivative, tumor cell growth, respiration, inhibition, cytotoxicity, 353
- Baboon, amyloidosis, colon, 725
- Baboons, amyloidosis, stomach, 663
- Baboons, esophagus, lymphocytes, inflammation, 613
- Baboons, glassy cells, gastric, humans, 9
- Baboons, lymphocytes, gastritis, frequency, non-human primates, 101
- BALB/c mice, curcumin, WEHI-3 leukemia cells, cytotoxicity, 63
- Base of tongue cancer, radiotherapy, salvage surgery, 803
- Bax, gypenosides, apoptosis, caspase-3, Bcl-2, *p53*, cell cycle, 215
- Bcl-2, gypenosides, apoptosis, caspase-3, Bax, *p53*, cell cycle, 215
- Bee venom (BV), MCF7 cells, apoptosis, caspase, ROS, mitochondria, 237
- Berberine, cell migration, NF- $\kappa$ B/p65, MMP-2, MMP-9, matrix metalloproteinase, 223
- BHA, butylmethoxyphenol, *bis*-BHA, radical-scavenging activity, theoretical parameters, 289
- Bioavailability, tamoxifen, 4-hydroxytamoxifen, morin, pharmacokinetics, rats, 391
- Biodistribution, monoclonal antibodies (MAb),  $^{188}\text{Re}$ , pretargeting, 321
- Biodistribution, recombinant human factor IX (rhFIX), radiolabeled, pharmacokinetics, pig, 693
- Biological cancer therapy, Equine sarcoid, immunotherapy, mitochondrial changes, regressing tumour tissue, 519
- Bioluminescence, rat thigh infection, *Staphylococcus aureus*, 667
- Biomarkers, oxidative stress, MDA, PC, CML, malondialdehyde, protein carbonyl, 525
- Biphasic pulses, carcinoma, cisplatin, electrochemotherapy, mitoxantrone, 51
- Biphasic pulses, cisplatin, cat, fibrosarcoma, radiation recall, 751
- Biphasic pulses, cisplatin, electrochemotherapy, hyaluronidase, 47
- Bis*-BHA, butylmethoxyphenol, BHA, radical-scavenging activity, theoretical parameters, 289
- Bis-bioreductive agents, NLNQ-1, hypoxic cytotoxins, radiosensitizers, 285
- Bone mineral, computed tomography, collagen membrane, alveolar ridge defects, dogs, 231
- Breast cancer, mammary cancer, rodent models, pregnancy, estrogen, progesterone, review, 191
- Breast cancer, Rorschach test, prolactin, maternal behaviour, HER 2-neu, 845
- Butylmethoxyphenol, BHA, *bis*-BHA, radical-scavenging activity, theoretical parameters, 289
- Cacao husk lignin, radical scavenging activity, anti-HIV activity, vitamin C, 327
- Cancer chemotherapy, faith, immunity, lung cancer, spirituality, 577
- Cancer chemotherapy, metronomic chemotherapy, endothelial progenitor cells, 831
- Cancer, proteoglycans, chondroitin sulfate, modified chondroitin sulfate, review, 385
- Cancer-resistant phenotype, SR/CR, litter seriation, 565
- Cancer-testis antigens, NY-ESO-1, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Carboplatin, carcinoid, dog, immunohistochemistry, surgery, 759
- Carcinogenesis, gene expression, ras, *Ha-ras*, *p53*, *c-myc*, MNU, DMBA, mice, 793
- Carcinoid, carboplatin, dog, immunohistochemistry, surgery, 759
- Carcinoma, biphasic pulses, cisplatin, electrochemotherapy, mitoxantrone, 51
- Cardiac remodelling, animal model, heart failure, review, 767
- B-Carotene, *Dunaliella salina*, apoptosis, A549, *p53*, NSCLS, 369
- Carotid, stavudine, protease inhibitors, color Doppler ultrasonography, atherosclerosis, HIV, 489
- Cartilage tissue engineering, Spongostan<sup>®</sup>, foreign body giant cells, rabbit, 203
- Caspase, bee venom (BV), MCF7 cells, apoptosis, ROS, mitochondria, 237
- Caspase-3, gypenosides, apoptosis, Bcl-2, Bax, *p53*, cell cycle, 215
- Cat, biphasic pulses, cisplatin, fibrosarcoma, radiation recall, 751
- Catalytic reduction, chlorambucil, 7-keto-steroids, antileukemic activity, SAR, steroidal esters, 345
- CD137L, interleukin-12, plasmocytoma, gene therapy, *in vivo*, 337

- CD44, HNSCC, permanent cell lines, tumor stem cell, 89
- Cell culture, eosinophilic chronic rhinosinusitis, ECRS, HGF, VCAM-1, sinusitis, 77
- Cell cycle, gypenosides, apoptosis, caspase-3, Bcl-2, Bax, *p53*, 215
- Cell migration, anti-metastatic, anti-angiogenic, medicinal plants, 363
- Cell migration, berberine, NF- $\kappa$ B/p65, MMP-2, MMP-9, matrix metalloproteinase, 223
- Celsior, liver, cold storage, reperfusion, UW, sinusoidal endothelial cells, glutathione, 681
- Central nervous system (CNS), astrocytes, glial fibrillary acidic protein (GFAP), lesion, tenascin-C (TN), 409
- Cetuximab, *EGFR* mutations, erlotinib, gefitinib, NSCLC, resistance to chemotherapy, review, 529
- C-fos*, *H-ras*, oral squamous cell carcinoma, immunohistochemistry, hamster, 621
- CGG expansion, fragile X syndrome, gray zone alleles, FMRP, population screening, 451
- Chalcones, multidrug resistance, MDR reversal, efflux pump, P-glycoprotein, 379
- Chemotherapy, cortisol rhythm, lymphocytopenia, psychoncology, 257
- Chemotherapy, imaging, lymphoma, prostate, dog, 755
- Chemotherapy, renal cell cancer, interleukin-2, metastatic disease, 481
- Childhood astrocytoma, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Childhood medulloblastoma, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Chinese medicine, glycyrrhizin, NO, PGE<sub>2</sub>, macrophage, 583
- Chinese medicine, Sairei-to, prostaglandin E<sub>2</sub>, phospholipase A2, cyclooxygenase-2, 571
- Chlorambucil, 7-keto-steroids, antileukemic activity, SAR, steroidal esters, catalytic reduction, 345
- Cholesterol, lipoproteins, coronary artery disease, genetic, polymorphism, ABCA1, VLDL, 187
- Chondroitin sulfate, proteoglycans, cancer, modified chondroitin sulfate, review, 385
- Chondrosarcoma, osteochondroma, HMO, exostosis, imaging, review, 633
- Choroidal melanoma, liver metastasis, laparoscopy, 807
- Chromosomal abnormality, aplastic anemia, DNA aneuploidy, flow cytometry, prognosis, 837
- Chromosome aberrations, adaptive response, oocytes, follicle culture, ionizing radiation, 179
- Chronic cholecystitis, gallstones, gallbladder, elderly, inflammation, 269
- Chronic fatigue syndrome, RNase L, elastase, protein kinase R, nitric oxide, daily functioning, 115
- Chronic fatigue syndrome, validation energy index point score, 799
- Chronic hepatitis, portal blood flow, Doppler ultrasonography, meal intake, liver cirrhosis, hyperdynamic syndrome, 509
- Chronic kidney disease (CKD), fatty acid composition, hemodialysis, polyunsaturated fatty acids (PUFA), 609
- Chronic rhinosinusitis, eosinophils, culture, functional endoscopic sinus surgery, 549
- Chronic rhinosinusitis, eosinophils, IL-5, IL-13, MMP-2, MMP-9, functional endoscopic sinus surgery, 415
- Chronic sinusitis, glucocorticoid, glucocorticoid receptor, nasal polyp, 37
- Cigarette smoking, NNK, colitis-associated colon cancer, 557
- Cisplatin, ABC transporter, copper transporter, drug resistance, microarray, pharmacogenomics, 279
- Cisplatin, biphasic pulses, carcinoma, electrochemotherapy, mitoxantrone, 51
- Cisplatin, biphasic pulses, cat, fibrosarcoma, radiation recall, 751
- Cisplatin, biphasic pulses, electrochemotherapy, hyaluronidase, 47
- Clusterin, atherosclerosis, coronary artery disease, apolipoprotein J, leptin, 537
- CML, oxidative stress, MDA, PC, biomarkers, malondialdehyde, protein carbonyl, 525
- C-myc, gene expression, carcinogenesis, ras, *Ha-ras*, *p53*, MNU, DMBA, mice, 793
- Cochlea, congenital cholesteatoma, extension, internal auditory canal, 651
- Cold storage, liver, reperfusion, UW, Celsior, sinusoidal endothelial cells, glutathione, 681
- Colitis-associated colon cancer, cigarette smoking, NNK, 557
- Collagen membrane, computed tomography, bone mineral, alveolar ridge defects, dogs, 231
- Colon cancer, digestive system, aberrant crypt foci (ACF), diethylstilbestrol (DES), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), rat, 699
- Colon, amyloidosis, baboon, 725
- Color Doppler ultrasonography, stavudine, protease inhibitors, carotid, atherosclerosis, HIV, 489
- Colorectal cancer, systemic sclerosis, paraneoplastic syndrome, 825
- Computed tomography, bone mineral, collagen membrane, alveolar ridge defects, dogs, 231
- Congenital cholesteatoma, extension, internal auditory canal, cochlea, 651

- Contrast medium, CVVH, contrast nephropathy, kidney failure, coronarography, 123
- Contrast nephropathy, CVVH, kidney failure, contrast medium, coronarography, 123
- Copper transporter, ABC transporter, cisplatin, drug resistance, microarray, pharmacogenomics, 279
- Coronarography, CVVH, contrast nephropathy, kidney failure, contrast medium, 123
- Coronary artery bypass, hepatocyte growth factor (HGF), gene therapy, coronary heart disease (CHD), 629
- Coronary artery disease, atherosclerosis, apolipoprotein J, clusterin, leptin, 537
- Coronary artery disease, DNA damage, oxidative stress, DNA repair, gene, 477
- Coronary artery disease, lipoproteins, genetic, polymorphism, ABCA1, VLDL, cholesterol, 187
- Coronary heart disease (CHD), hepatocyte growth factor (HGF), gene therapy, coronary artery bypass, 629
- Corticosterone, non-invasive stress assessment, ACTH, rats, 435
- Cortisol rhythm, chemotherapy, lymphocytopenia, psychoncology, 257
- Cortisol, interstitial pneumonia, drip infusion, megadose vitamin C, dehydroepiandrosterone, fortified adrenocortical elements, short review, 263
- CTAs, NY-ESO-1, cancer-testis antigens, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Culture, eosinophils, chronic rhinosinusitis, functional endoscopic sinus surgery, 549
- Curcumin, DHPN (*N*-bis(2-hydroxypropyl)nitrosamine, tumorigenesis BALB/c mice, *in vivo*, 781
- Curcumin, WEHI-3 leukemia cells, BALB/c mice, cytotoxicity, 63
- CVVH, contrast nephropathy, kidney failure, contrast medium, coronarography, 123
- Cyclooxygenase-1, *Rikko-san*, Kampo medicine, prostaglandin E<sub>2</sub>, cyclooxygenase-2, nitrosylation, 333
- Cyclooxygenase-2, chinese medicine, Sairei-to, prostaglandin E<sub>2</sub>, phospholipase A<sub>2</sub>, 571
- Cyclooxygenase-2, *Rikko-san*, Kampo medicine, prostaglandin E<sub>2</sub>, cyclooxygenase-1, nitrosylation, 333
- Cyst fluid, lymphangioma, cytokines, OK-432, 253
- Cytodifferentiation, sulfuraphane, apoptosis, granulocytes, macrophages, HL-60 cells, 317
- Cytokeratin, histone, modulation, hepatocellular carcinoma, immunoprecipitation, 457
- Cytokeratin, plectin, hepatocellular carcinoma, staurosporine, apoptosis, 543
- Cytokines, lymphangioma, cyst fluid, OK-432, 253
- Cytomegalovirus, antitumor promotion, *Euonymus* species, dihydro- $\beta$ -agarofuran, sesquiterpene, IE antigen expression, 787
- Cytotoxicity, curcumin, WEHI-3 leukemia cells, BALB/c mice, 63
- Cytotoxicity, nordihydroguaiaretic acid derivative, tumor cell growth, respiration, ATP level, inhibition, 353
- Daily functioning, RNase L, elastase, protein kinase R, nitric oxide, chronic fatigue syndrome, 115
- Dehydroepiandrosterone, interstitial pneumonia, drip infusion, megadose vitamin C, cortisol, fortified adrenocortical elements, short review, 263
- Detection, <sup>18</sup>F-FDG, multiple myeloma, positron emission tomography, plasmocytoma, 513
- DHPN (*N*-bis(2-hydroxypropyl)nitrosamine, curcumin, tumorigenesis BALB/c mice, *in vivo*, 781
- Diethylstilbestrol (DES), colon cancer, digestive system, aberrant crypt foci (ACF), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), rat, 699
- Diethylstilbestrol (DES), mammary carcinoma, mammary dysplasia, endocrine disruptor, 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), neonatal, rat, 207
- Differential diagnosis, well-differentiated thyroid carcinoma, thyroid incidentaloma, follow-up, serum thyroglobulin levels, <sup>18</sup>F-FDG PET, review, 109
- Difficult body areas, polyurethane sponge, tie-over, skin graft, wound bed, 503
- Digestive system, colon cancer, aberrant crypt foci (ACF), diethylstilbestrol (DES), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), rat, 699
- Dihydro- $\beta$ -agarofuran, antitumor promotion, *Euonymus* species, sesquiterpene, cytomegalovirus, IE antigen expression, 787
- Diindolylmethane (DIM), indole-3-carbinol (I3C), pro-drug, activity, review, 441
- 7,12-Dimethylbenz[ $\alpha$ ]anthracene (DMBA), mammary carcinoma, mammary dysplasia, diethylstilbestrol (DES), endocrine disruptor, neonatal, rat, 207
- 7,12-Dimethylbenz[ $\alpha$ ]anthracene (DMBA), colon cancer, digestive system, aberrant crypt foci (ACF), diethylstilbestrol (DES), rat, 699
- DMBA, gene expression, carcinogenesis, ras, *Ha-ras*, *p53*, *c-myc*, MNU, mice, 793
- DNA aneuploidy, aplastic anemia, flow cytometry, prognosis, chromosomal abnormality, 837
- DNA breaks, DNA damage and repair, H2AX, lethal damage, review, 305
- DNA damage and repair, DNA breaks, H2AX, lethal damage, review, 305
- DNA damage, coronary artery disease, oxidative stress, DNA repair, gene, 477
- DNA repair, DNA damage, coronary artery disease, oxidative stress, gene, 477

- Dog, carboplatin, carcinoid, immunohistochemistry, surgery, 759
- Dog, chemotherapy, imaging, lymphoma, prostate, 755
- Dog, MMP-9, E-cadherin, Ki-67 protein, adenocarcinomas, 463
- Dogs, computed tomography, bone mineral, collagen membrane, alveolar ridge defects, 231
- Doppler ultrasonography, portal blood flow, meal intake, chronic hepatitis, liver cirrhosis, hyperdynamic syndrome, 509
- Drip infusion, interstitial pneumonia, megadose vitamin C, dehydroepiandrosterone, cortisol, fortified adrenocortical elements, short review, 263
- Drug resistance, ABC transporter, cisplatin, copper transporter, microarray, pharmacogenomics, 279
- DTPA, estrone derivatives, <sup>99m</sup>Tc, estrogen receptor, 93
- Dunaliella salina*,  $\beta$ -carotene, apoptosis, A549, p53, NSCLS, 369
- E-cadherin, MMP-9, Ki-67 protein, adenocarcinomas, dog, 463
- Eccrine spiradenoma, histopathological subtype, anatomical distribution, 821
- ECRS, eosinophilic chronic rhinosinusitis, HGF, VCAM-1, cell culture, sinusitis, 77
- Ectopic endometriosis, umbilical reconstruction, 811
- Efflux pump inhibitors, macrophages, enhanced killing, *Mycobacterium tuberculosis*, *ex vivo* studies, 69
- Efflux pump, Chalcones, multidrug resistance, MDR reversal, P-glycoprotein, 379
- EGFR* mutations, cetuximab, erlotinib, gefitinib, NSCLC, resistance to chemotherapy, review, 529
- Elastase, RNase L, protein kinase R, nitric oxide, chronic fatigue syndrome, daily functioning, 115
- Elderly, chronic cholecystitis, gallstones, gallbladder, inflammation, 269
- Electrochemotherapy, biphasic pulses, carcinoma, cisplatin, mitoxantrone, 51
- Electrochemotherapy, biphasic pulses, cisplatin, hyaluronidase, 47
- E-mail survey, gynecological, morbidity, menstrual cycle, 617
- Endocrine disruptor, mammary carcinoma, mammary dysplasia, diethylstilbestrol (DES), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), neonatal, rat, 207
- Endocrine disruptors, 4-*tert*-octylphenol, incubation, frog, *Rana japonica*, 105
- Endothelial cells, aged, mice, nitric oxide, aortic rings, angiogenesis, wound repair, 673
- Endothelial progenitor cells, metronomic chemotherapy, cancer chemotherapy, 831
- Endotoxemia, experimental liver cirrhosis, messenger ribonucleic acid, rats, IGF-I, 655
- Energy expenditure, hypothermia, Harris-Benedict, indirect calorimetry, 143
- Enhanced killing, macrophages, *Mycobacterium tuberculosis*, efflux pump inhibitors, *ex vivo* studies, 69
- Eosinophil, epinastine hydrochloride, nasal epithelial cells, H1 receptor antagonist, 687
- Eosinophil, epinastine, activation, suppression, 13
- Eosinophilic chronic rhinosinusitis, ECRS, HGF, VCAM-1, cell culture, sinusitis, 77
- Eosinophils, chronic rhinosinusitis, culture, functional endoscopic sinus surgery, 549
- Eosinophils, chronic rhinosinusitis, IL-5, IL-13, MMP-2, MMP-9, functional endoscopic sinus surgery, 415
- Epinastine hydrochloride, eosinophil, nasal epithelial cells, H1 receptor antagonist, 687
- Epinastine, eosinophil, activation, suppression, 13
- Equine sarcoid, immunotherapy, biological cancer therapy, mitochondrial changes, regressing tumour tissue, 519
- Erlotinib, cetuximab, *EGFR* mutations, gefitinib, NSCLC, resistance to chemotherapy, review, 529
- Erythrocytes, ionizing radiation, space radiation, solar flare, particle radiation, gamma-rays, spleen, leukocytes, thrombocytes, 159
- Erythropoietin, angiogenesis, growth factors, mouse heart, 587
- Esophagitis, reflux, non-human primates indent, 721
- Esophagus, baboons, lymphocytes, inflammation, 613
- Estrogen receptor, estrone derivatives, <sup>99m</sup>Tc, DTPA, 93
- Estrogen, breast cancer, mammary cancer, rodent models, pregnancy, progesterone, review, 191
- Estrone derivatives, <sup>99m</sup>Tc, estrogen receptor, DTPA, 93
- Euonymus* species, antitumor promotion, dihydro- $\beta$ -agarofuran, sesquiterpene, cytomegalovirus, IE antigen expression, 787
- Ex vivo* studies, macrophages, enhanced killing, *Mycobacterium tuberculosis*, efflux pump inhibitors, 69
- Excitotoxicity, amyotrophic lateral sclerosis, glutamate, glycine, plasma, 137
- Exostosis, osteochondroma, HMO, chondrosarcoma, imaging, review, 633
- Experimental liver cirrhosis, endotoxemia, messenger ribonucleic acid, rats, IGF-I, 655
- Extension, congenital cholesteatoma, internal auditory canal, cochlea, 651
- Extracellular matrix, fibrosis, muscle damage, muscle inflammation, transforming growth factor  $\beta$ 1, urokinase-type plasminogen activator, review, 735
- Faith, cancer chemotherapy, immunity, lung cancer, spirituality, 577
- Fatty acid composition, chronic kidney disease (CKD), hemodialysis, polyunsaturated fatty acids (PUFA), 609
- <sup>18</sup>F-FDG, multiple myeloma, positron emission tomography, plasmocytoma, detection, 513
- <sup>18</sup>F-FDG PET, well-differentiated thyroid carcinoma, thyroid incidentaloma, differential diagnosis, follow-up, serum thyroglobulin levels, review, 109

- FDG-PET/CT, rat model, head and neck squamous cell carcinoma, allograft, 403
- Fibroblasts, radiation wound, MMP, TGF-beta, 1
- Fibrosarcoma, biphasic pulses, cisplatin, cat, radiation recall, 751
- Fibrosis, extracellular matrix, muscle damage, muscle inflammation, transforming growth factor  $\beta$ 1, urokinase-type plasminogen activator, review, 735
- Fish intake, age, gender, Omega-3 Index, physical activity, 131
- Flow cytometry, aplastic anemia, DNA aneuploidy, prognosis, chromosomal abnormality, 837
- FMRP, fragile X syndrome, CGG expansion, gray zone alleles, population screening, 451
- Follicle culture, adaptive response, oocytes, ionizing radiation, chromosome aberrations, 179
- Follow-up, well-differentiated thyroid carcinoma, thyroid incidentaloma, differential diagnosis, serum thyroglobulin levels,  $^{18}\text{F}$ -FDG PET, review, 109
- Foreign body giant cells, Spongostan<sup>®</sup>, cartilage tissue engineering, rabbit, 203
- Fortified adrenocortical elements, interstitial pneumonia, drip infusion, megadose vitamin C, dehydroepiandrosterone, cortisol, short review, 263
- Fragile X syndrome, CGG expansion, gray zone alleles, FMRP, population screening, 451
- Frequency, lymphocytes, gastritis, baboons, non-human primates, 101
- Frog, 4-*tert*-octylphenol, endocrine disruptors, incubation, *Rana japonica*, 105
- Functional endoscopic sinus surgery, eosinophils, chronic rhinosinusitis, culture, 549
- Functional endoscopic sinus surgery, eosinophils, chronic rhinosinusitis, IL-5, IL-13, MMP-2, MMP-9, 415
- Gallbladder, chronic cholecystitis, gallstones, elderly, inflammation, 269
- Gallstones, chronic cholecystitis, gallbladder, elderly, inflammation, 269
- Gamma radiation, ionizing radiation, immune system, lymphocytes, leukocytes, 423
- Gamma-rays, ionizing radiation, space radiation, solar flare, particle radiation, spleen, leukocytes, erythrocytes, thrombocytes, 159
- Gastric cancer, advanced and recurrent, adjuvant therapy, new drugs, review, 273
- Gastric cancer, lymph node metastasis, micrometastasis, isolated tumor cells, neoadjuvant chemotherapy, 707
- Gastric, glassy cells, baboons, humans, 9
- Gastritis, lymphocytes, frequency, baboons, non-human primates, 101
- Gefitinib, cetuximab, *EGFR* mutations, erlotinib, NSCLC, resistance to chemotherapy, review, 529
- Geldamycin, heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP 90, HSP inhibitors, 17-allyl-17-dimethoxygeldanamycin, review, 311
- Gender, age, fish intake, Omega-3 Index, physical activity, 131
- Gene expression, carcinogenesis, ras, *Ha-ras*, *p53*, *c-myc*, MNU, DMBA, mice, 793
- Gene therapy, CD137L, interleukin-12, plasmocytoma, *in vivo*, 337
- Gene therapy, hepatocyte growth factor (HGF), coronary heart disease (CHD), coronary artery bypass, 629
- Gene, DNA damage, coronary artery disease, oxidative stress, DNA repair, 477
- Genetic, lipoproteins, coronary artery disease, polymorphism, ABCA1, VLDL, cholesterol, 187
- Glassy cells, gastric, baboons, humans, 9
- Glial fibrillary acidic protein (GFAP), astrocytes, central nervous system (CNS), lesion, tenascin-C (TN), 409
- Glucocorticoid receptor, glucocorticoid, nasal polyp, chronic sinusitis, 37
- Glucocorticoid, glucocorticoid receptor, nasal polyp, chronic sinusitis, 37
- Glutamate, amyotrophic lateral sclerosis, glycine, excitotoxicity, plasma, 137
- Glutathione, liver, cold storage, reperfusion, UW, Celsior, sinusoidal endothelial cells, 681
- Glycine, amyotrophic lateral sclerosis, glutamate, excitotoxicity, plasma, 137
- Glycyrrhizin, Chinese medicine, NO, PGE<sub>2</sub>, macrophage, 583
- Granulocytes, sulfuraphane, apoptosis, cytodifferentiation, macrophages, HL-60 cells, 317
- Gray zone alleles, fragile X syndrome, CGG expansion, FMRP, population screening, 451
- Growth factors, angiogenesis, erythropoietin, mouse heart, 587
- Gynecological, e-mail survey, morbidity, menstrual cycle, 617
- Gypenosides, apoptosis, caspase-3, Bcl-2, Bax, *p53*, cell cycle, 215
- H1 receptor antagonist, eosinophil, epinastine hydrochloride, nasal epithelial cells, 687
- H2AX, DNA breaks, DNA damage and repair, lethal damage, review, 305
- Hamster, *H-ras*, *c-fos*, oral squamous cell carcinoma, immunohistochemistry, 621
- Ha-ras*, gene expression, carcinogenesis, ras, *p53*, *c-myc*, MNU, DMBA, mice, 793
- Harris-Benedict, hypothermia, indirect calorimetry, energy expenditure, 143
- Head and neck squamous cell carcinoma, rat model, allograft, FDG-PET/CT, 403
- Heart failure, animal model, cardiac remodelling, review, 767



- Heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP 90, HSP inhibitors, geldamycin, 17-allyl-17-dimethoxygeldanamycin, review, 311
- Hemodialysis, chronic kidney disease (CKD), fatty acid composition, polyunsaturated fatty acids (PUFA), 609
- Hepatocellular carcinoma, cytokeratin, histone, modulation, immunoprecipitation, 457
- Hepatocellular carcinoma, cytokeratin, plectin, staurosporine, apoptosis, 543
- Hepatocyte growth factor (HGF), gene therapy, coronary heart disease (CHD), coronary artery bypass, 629
- HER 2-neu, breast cancer, Rorschach test, prolactin, maternal behaviour, 845
- HGF, eosinophilic chronic rhinosinusitis, ECRS, VCAM-1, cell culture, sinusitis, 77
- HIPEC, multicystic peritoneal mesothelioma, peritonectomy, hyperthermic intra-peritoneal chemotherapy, 153
- Histone, cytokeratin, modulation, hepatocellular carcinoma, immunoprecipitation, 457
- Histopathological subtype, eccrine spiradenoma, anatomical distribution, 821
- HIV, HPV, saliva, oral cancer, molecular testing, 599
- HIV, stavudine, protease inhibitors, color Doppler ultrasonography, carotid, atherosclerosis, 489
- HL-60 cells, sulforaphane, apoptosis, cytodifferentiation, granulocytes, macrophages, 317
- HMO, osteochondroma, exostosis, chondrosarcoma, imaging, review, 633
- HNSCC, permanent cell lines, CD44, tumor stem cell, 89
- HPV, HIV, saliva, oral cancer, molecular testing, 599
- H-ras*, *c-fos*, oral squamous cell carcinoma, immunohistochemistry, hamster, 621
- HSP 90, heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP inhibitors, geldamycin, 17-allyl-17-dimethoxygeldanamycin, review, 311
- HSP inhibitors, heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP 90, geldamycin, 17-allyl-17-dimethoxygeldanamycin, review, 311
- Human skeletal muscle, IGF-1 isoforms, rat myocardium, MGF peptide, MGF antibody, 27
- Humans, glassy cells, gastric, baboons, 9
- Hyaluronidase, biphasic pulses, cisplatin, electrochemotherapy, 47
- 4-Hydroxytamoxifen, tamoxifen, morin, pharmacokinetics, bioavailability, rats, 391
- Hyperdynamic syndrome, portal blood flow, Doppler ultrasonography, meal intake, chronic hepatitis, liver cirrhosis, 509
- Hyperthermic intra-peritoneal chemotherapy, multicystic peritoneal mesothelioma, peritonectomy, HIPEC, 153
- Hypopharynx tumor, inflammatory pseudotumor, IPT, Inflammatory myofibroblastic tumor, plasma cell granuloma, 817
- Hypothermia, Harris-Benedict, indirect calorimetry, energy expenditure, 143
- Hypothyroidism, aorta, 8-oxod-G, oxidative stress, 603
- Hypoxic cytotoxins, NLNQ-1, radiosensitizers, bis-bioreductive agents, 285
- IE antigen expression, antitumor promotion, *Euonymus* species, dihydro- $\beta$ -agarofuran, sesquiterpene, cytomegalovirus, 787
- IGF-1 isoforms, human skeletal muscle, rat myocardium, MGF peptide, MGF antibody, 27
- IGF-I, experimental liver cirrhosis, endotoxemia, messenger ribonucleic acid, rats, 655
- IL-13, eosinophils, chronic rhinosinusitis, IL-5, MMP-2, MMP-9, functional endoscopic sinus surgery, 415
- IL-5, eosinophils, chronic rhinosinusitis, IL-13, MMP-2, MMP-9, functional endoscopic sinus surgery, 415
- IL-9R $\alpha$ , T-cell lymphoma, Stat, strain difference, 713
- Imaging, chemotherapy, lymphoma, prostate, dog, 755
- Imaging, osteochondroma, HMO, exostosis, chondrosarcoma, review, 633
- Immune escape, NK cell-mediated cytotoxicity, oral cancer, MMP-2, MMP-9, 593
- Immune system, ionizing radiation, gamma radiation, lymphocytes, leukocytes, 423
- Immunity, cancer chemotherapy, faith, lung cancer, spirituality, 577
- Immunocytochemistry, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, monoclonal antibody, MoAB, antigen retrieval, 83
- Immunohistochemistry, carboplatin, carcinoid, dog, surgery, 759
- Immunohistochemistry, *H-ras*, *c-fos*, oral squamous cell carcinoma, hamster, 621
- Immunohistochemistry, non-papillary lesions, urothelium, urinary bladder, review, 493
- Immunophenotype, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Immunoprecipitation, cytokeratin, histone, modulation, hepatocellular carcinoma, 457
- Immunosuppression, anticancer immunity, lymphocytes, T-regulator lymphocytes, 647
- Immunotherapy, Equine sarcoid, biological cancer therapy, mitochondrial changes, regressing tumour tissue, 519
- In vivo*, CD137L, interleukin-12, plasmacytoma, gene therapy, 337

- In vivo*, curcumin, DHPN (*N*-bis(2-hydroxypropyl) nitrosamine, tumorigenesis BALB/c mice, 781
- Incubation, 4-*tert*-octylphenol, endocrine disruptors, frog, *Rana japonica*, 105
- Indirect calorimetry, hypothermia, Harris-Benedict, energy expenditure, 143
- Indole-3-carbinol (I3C), diindolylmethane (DIM), pro-drug, activity, review, 441
- Inflammation, chronic cholecystitis, gallstones, gallbladder, elderly, 269
- Inflammation, esophagus, baboons, lymphocytes, 613
- Inflammatory myofibroblastic tumor, inflammatory pseudotumor, IPT, plasma cell granuloma, hypopharynx tumor, 817
- Inflammatory pseudotumor, IPT, Inflammatory myofibroblastic tumor, plasma cell granuloma, hypopharynx tumor, 817
- Inhibition of nitric oxide synthesis, nitric oxide, progestational agents, preterm birth, 447
- Inhibition, nordihydroguaiaretic acid derivative, tumor cell growth, respiration, ATP level, cytotoxicity, 353
- Interleukin-12, CD137L, plasmocytoma, gene therapy, *in vivo*, 337
- Interleukin-2, ionizing radiations, pineal hormones, radiotherapy, 397
- Interleukin-2, renal cell cancer, chemotherapy, metastatic disease, 481
- Internal auditory canal, congenital cholesteatoma, extension, cochlea, 651
- Interstitial pneumonia, drip infusion, megadose vitamin C, dehydroepiandrosterone, cortisol, fortified adrenocortical elements, short review, 263
- Ionizing radiation, adaptive response, oocytes, follicle culture, chromosome aberrations, 179
- Ionizing radiation, gamma radiation, immune system, lymphocytes, leukocytes, 423
- Ionizing radiation, space radiation, solar flare, particle radiation, gamma-rays, spleen, leukocytes, erythrocytes, thrombocytes, 159
- Ionizing radiations, interleukin-2, pineal hormones, radiotherapy, 397
- IP, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- IPT, inflammatory pseudotumor, Inflammatory myofibroblastic tumor, plasma cell granuloma, hypopharynx tumor, 817
- Ischaemia, leptin, surgical flaps, survival rate, wound healing, angiogenesis, 247
- Isolated tumor cells, gastric cancer, lymph node metastasis, micrometastasis, neoadjuvant chemotherapy, 707
- Kampo medicine, *Rikko-san*, prostaglandin E<sub>2</sub>, cyclooxygenase-1, cyclooxygenase-2, nitrosylation, 333
- 7-Keto-steroids, chlorambucil, antileukemic activity, SAR, steroidal esters, catalytic reduction, 345
- Ki-67 protein, MMP-9, E-cadherin, adenocarcinomas, dog, 463
- Kidney failure, CVVH, contrast nephropathy, contrast medium, coronarography, 123
- Laparoscopy, choroidal melanoma, liver metastasis, 807
- Leptin, atherosclerosis, coronary artery disease, apolipoprotein J, clusterin, 537
- Leptin, surgical flaps, survival rate, ischaemia, wound healing, angiogenesis, 247
- Lesion, astrocytes, central nervous system (CNS), glial fibrillary acidic protein (GFAP), tenascin-C (TN), 409
- Lethal damage, DNA breaks, DNA damage and repair, H2AX, review, 305
- Leukocytes, ionizing radiation, gamma radiation, immune system, lymphocytes, 423
- Leukocytes, ionizing radiation, space radiation, solar flare, particle radiation, gamma-rays, spleen, erythrocytes, thrombocytes, 159
- Lignin, SE, radical-scavenging activity, anti-HIV activity, antibacterial activity, vitamin C, 471
- Lipoproteins, coronary artery disease, genetic, polymorphism, ABCA1, VLDL, cholesterol, 187
- Litter seriation, cancer-resistant phenotype, SR/CR, 565
- Liver cirrhosis, portal blood flow, Doppler ultrasonography, meal intake, chronic hepatitis, hyperdynamic syndrome, 509
- Liver metastasis, choroidal melanoma, laparoscopy, 807
- Liver, cold storage, reperfusion, UW, Celsior, sinusoidal endothelial cells, glutathione, 681
- Lung cancer, cancer chemotherapy, faith, immunity, spirituality, 577
- Luteolin, *N*-acetyltransferase (NAT), 2-aminofluorene (2-AF), *N*-acetyl-2-aminofluorene (2-AAF), 2-AF metabolites, 729
- Lymph node metastasis, gastric cancer, micrometastasis, isolated tumor cells, neoadjuvant chemotherapy, 707
- Lymphangioma, cyst fluid, cytokines, OK-432, 253
- Lymphocytes, anticancer immunity, immunosuppression, T-regulator lymphocytes, 647
- Lymphocytes, esophagus, baboons, inflammation, 613
- Lymphocytes, gastritis, frequency, baboons, non-human primates, 101
- Lymphocytes, ionizing radiation, gamma radiation, immune system, leukocytes, 423
- Lymphocytopenia, chemotherapy, cortisol rhythm, psychoncology, 257
- Lymphoma, *Atelerix albiventris*, skin, surgery, T-cell, 43
- Lymphoma, chemotherapy, imaging, prostate, dog, 755
- Macrophage, glycyrrhizin, Chinese medicine, NO, PGE<sub>2</sub>, 583

- Macrophages, enhanced killing, *Mycobacterium tuberculosis*, efflux pump inhibitors, *ex vivo* studies, 69
- Macrophages, sulforaphane, apoptosis, cytodifferentiation, granulocytes, HL-60 cells, 317
- Malondialdehyde, oxidative stress, MDA, PC, CML, biomarkers, protein carbonyl, 525
- Mammary cancer, breast cancer, rodent models, pregnancy, estrogen, progesterone, review, 191
- Mammary carcinoma, mammary dysplasia, diethylstilbestrol (DES), endocrine disruptor, 7,12-dimethylbenz[ $\alpha$ ] anthracene (DMBA), neonatal, rat, 207
- Mammary dysplasia, mammary carcinoma, diethylstilbestrol (DES), endocrine disruptor, 7,12-dimethylbenz[ $\alpha$ ] anthracene (DMBA), neonatal, rat, 207
- Maternal behaviour, breast cancer, Rorschach test, prolactin, HER 2-neu, 845
- Matrix metalloproteinase, berberine, cell migration, NF- $\kappa$ B/p65, MMP-2, MMP-9, 223
- MCF7 cells, bee venom (BV), apoptosis, caspase, ROS, mitochondria, 237
- MDA, oxidative stress, PC, CML, biomarkers, malondialdehyde, protein carbonyl, 525
- MDR reversal, Chalcones, multidrug resistance, efflux pump, P-glycoprotein, 379
- Meal intake, portal blood flow, Doppler ultrasonography, chronic hepatitis, liver cirrhosis, hyperdynamic syndrome, 509
- MED, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Medicinal plants, anti-metastatic, anti-angiogenic, cell migration, 363
- Megadose vitamin C, interstitial pneumonia, drip infusion, dehydroepiandrosterone, cortisol, fortified adrenocortical elements, short review, 263
- Menstrual cycle, e-mail survey, gynecological, morbidity, 617
- Messenger ribonucleic acid, experimental liver cirrhosis, endotoxemia, rats, IGF-I, 655
- Metastatic disease, renal cell cancer, interleukin-2, chemotherapy, 481
- Methicillin-resistant *Staphylococcus aureus*, octylcyanoacrylate, antibacterial effect, methicillin-sensitive *Staphylococcus aureus*, otorrhea, 763
- Methicillin-sensitive *Staphylococcus aureus*, octylcyanoacrylate, antibacterial effect, methicillin-resistant *Staphylococcus aureus*, otorrhea, 763
- 2-Methoxyestradiol, apoptosis, rat osteosarcoma, rat malignant fibrous histiocytoma, 21
- Methylene blue, photodynamic therapy, acridine orange, osteosarcoma, 297
- Metronomic chemotherapy, endothelial progenitor cells, cancer chemotherapy, 831
- MGF antibody, IGF-1 isoforms, human skeletal muscle, rat myocardium, MGF peptide, 27
- MGF peptide, IGF-1 isoforms, human skeletal muscle, rat myocardium, MGF antibody, 27
- Mice, aged, endothelial cells, nitric oxide, aortic rings, angiogenesis, wound repair, 673
- Mice, gene expression, carcinogenesis, ras, *Ha-ras*, *p53*, *c-myc*, MNU, DMBA, 793
- Microarray, ABC transporter, cisplatin, copper transporter, drug resistance, pharmacogenomics, 279
- Micrometastasis, gastric cancer, lymph node metastasis, isolated tumor cells, neoadjuvant chemotherapy, 707
- Mitochondria, bee venom (BV), MCF7 cells, apoptosis, caspase, ROS, 237
- Mitochondrial changes, Equine sarcoid, immunotherapy, biological cancer therapy, regressing tumour tissue, 519
- Mitoxantrone, biphasic pulses, carcinoma, cisplatin, electrochemotherapy, 51
- MMP, fibroblasts, radiation wound, TGF-beta, 1
- MMP-2, berberine, cell migration, NF- $\kappa$ B/p65, MMP-9, matrix metalloproteinase, 223
- MMP-2, eosinophils, chronic rhinosinusitis, IL-5, IL-13, MMP-9, functional endoscopic sinus surgery, 415
- MMP-2, NK cell-mediated cytotoxicity, immune escape, oral cancer, MMP-9, 593
- MMP-9, berberine, cell migration, NF- $\kappa$ B/p65, MMP-2, matrix metalloproteinase, 223
- MMP-9, E-cadherin, Ki-67 protein, adenocarcinomas, dog, 463
- MMP-9, eosinophils, chronic rhinosinusitis, IL-5, IL-13, MMP-2, functional endoscopic sinus surgery, 415
- MMP-9, NK cell-mediated cytotoxicity, immune escape, oral cancer, MMP-2, 593
- MnSOD, polymorphism, superoxide dismutase, open heart surgery, 147
- MNU, gene expression, carcinogenesis, ras, *Ha-ras*, *p53*, *c-myc*, DMBA, mice, 793
- MoAB, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, antigen retrieval, 83
- Modified chondroitin sulfate, proteoglycans, chondroitin sulfate, cancer, review, 385
- Modulation, cytokeratin, histone, hepatocellular carcinoma, immunoprecipitation, 457

- Molecular chaperones, heat shock proteins (HSPs), anticancer agents, HSP 90, HSP inhibitors, geldamycin, 17-allyl-17-dimethoxygeldanamycin, review, 311
- Molecular testing, HPV, HIV, saliva, oral cancer, 599
- Monoclonal antibodies (MAb),  $^{188}\text{Re}$ , pretargeting, biodistribution, 321
- Monoclonal antibody, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, MoAB, antigen retrieval, 83
- Morbidity, e-mail survey, gynecological, menstrual cycle, 617
- Morin, tamoxifen, 4-hydroxytamoxifen, pharmacokinetics, bioavailability, rats, 391
- Mouse heart, angiogenesis, erythropoietin, growth factors, 587
- $^{99\text{m}}\text{Tc}$ , estrone derivatives, estrogen receptor, DTPA, 93
- Multicystic peritoneal mesothelioma, peritonectomy, hyperthermic intra-peritoneal chemotherapy, HIPEC, 153
- Multidrug resistance, Chalcones, MDR reversal, efflux pump, P-glycoprotein, 379
- Multiple myeloma,  $^{18}\text{F}$ -FDG, positron emission tomography, plasmocytoma, detection, 513
- Muscle damage, extracellular matrix, fibrosis, muscle inflammation, transforming growth factor  $\beta$ 1, urokinase-type plasminogen activator, review, 735
- Muscle inflammation, extracellular matrix, fibrosis, muscle damage, transforming growth factor  $\beta$ 1, urokinase-type plasminogen activator, review, 735
- Mycobacterium tuberculosis*, macrophages, enhanced killing, efflux pump inhibitors, *ex vivo* studies, 69
- N*-acetyl-2-aminofluorene (2-AAF), luteolin, *N*-acetyltransferase (NAT), 2-aminofluorene (2-AF), 2-AF metabolites, 729
- N*-acetyltransferase (NAT), luteolin, 2-aminofluorene (2-AF), *N*-acetyl-2-aminofluorene (2-AAF), 2-AF metabolites, 729
- NAMs, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Nasal epithelial cells, eosinophil, epinastine hydrochloride, H1 receptor antagonist, 687
- Nasal polyp, glucocorticoid, glucocorticoid receptor, chronic sinusitis, 37
- Natural killer cells, osteopontin, pregnancy, progesterone, abortion, 55
- Neoadjuvant chemotherapy, gastric cancer, lymph node metastasis, micrometastasis, isolated tumor cells, 707
- Neonatal, mammary carcinoma, mammary dysplasia, diethylstilbestrol (DES), endocrine disruptor, 7,12-dimethylbenz[ $\alpha$ ] anthracene (DMBA), rat, 207
- Neoplasm associated markers, NY-ESO-1, cancer-testis antigens, CTAs, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- New drugs, gastric cancer, advanced and recurrent, adjuvant therapy, review, 273
- NF- $\kappa$ B/p65, berberine, cell migration, MMP-2, MMP-9, matrix metalloproteinase, 223
- Nitric oxide, aged, mice, endothelial cells, aortic rings, angiogenesis, wound repair, 673
- Nitric oxide, inhibition of nitric oxide synthesis, progestational agents, preterm birth, 447
- Nitric oxide, RNase L, elastase, protein kinase R, chronic fatigue syndrome, daily functioning, 115
- Nitrosylation, *Rikko-san*, Kampo medicine, prostaglandin  $\text{E}_2$ , cyclooxygenase-1, cyclooxygenase-2, 333
- NK cell-mediated cytotoxicity, immune escape, oral cancer, MMP-2, MMP-9, 593
- NLNQ-1, hypoxic cytotoxins, radiosensitizers, bis-bioreductive agents, 285
- NNK, cigarette smoking, colitis-associated colon cancer, 557
- NO, glycyrrhizin, Chinese medicine,  $\text{PGE}_2$ , macrophage, 583
- Non-human primates indent, esophagitis, reflux, 721
- Non-human primates, lymphocytes, gastritis, frequency, baboons, 101
- Non-invasive stress assessment, corticosterone, ACTH, rats, 435
- Non-papillary lesions, urothelium, urinary bladder, immunohistochemistry, review, 493
- Nordihydroguaiaretic acid derivative, tumor cell growth, respiration, ATP level, inhibition, cytotoxicity, 353
- NSCLC, cetuximab, *EGFR* mutations, erlotinib, gefitinib, resistance to chemotherapy, review, 529
- NSCLS, *Dunaliella salina*,  $\beta$ -carotene, apoptosis, A549, p53, 369
- NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Octylcyanoacrylate, antibacterial effect, methicillin-resistant *Staphylococcus aureus*, methicillin-sensitive *Staphylococcus aureus*, otorrhea, 763
- OK-432, lymphangioma, cyst fluid, cytokines, 253
- Omega-3 Index, age, fish intake, gender, physical activity, 131
- Oocytes, adaptive response, follicle culture, ionizing radiation, chromosome aberrations, 179

- Open heart surgery, polymorphism, MnSOD, superoxide dismutase, 147
- Oral cancer, HPV, HIV, saliva, molecular testing, 599
- Oral cancer, NK cell-mediated cytotoxicity, immune escape, MMP-2, MMP-9, 593
- Oral squamous cell carcinoma, *H-ras*, *c-fos*, immunohistochemistry, hamster, 621
- Osteochondroma, HMO, exostosis, chondrosarcoma, imaging, review, 633
- Osteopontin, pregnancy, natural killer cells, progesterone, abortion, 55
- Osteosarcoma, methylene blue, photodynamic therapy, acridine orange, 297
- Otorrhea, octylcyanoacrylate, antibacterial effect, methicillin-resistant *Staphylococcus aureus*, methicillin-sensitive *Staphylococcus aureus*, 763
- Oxidative stress, DNA damage, coronary artery disease, DNA repair, gene, 477
- Oxidative stress, hypothyroidism, aorta, 8-oxod-G, 603
- Oxidative stress, MDA, PC, CML, biomarkers, malondialdehyde, protein carbonyl, 525
- 8-Oxod-G, hypothyroidism, aorta, oxidative stress, 603
- P53, *Dunaliella salina*,  $\beta$ -carotene, apoptosis, A549, NSCLS, 369
- P53, gene expression, carcinogenesis, ras, *Ha-ras*, *c-myc*, MNU, DMBA, mice, 793
- P53, gypenosides, apoptosis, caspase-3, Bcl-2, Bax, cell cycle, 215
- Paraneoplastic syndrome, systemic sclerosis, colorectal cancer, 825
- Particle radiation, ionizing radiation, space radiation, solar flare, gamma-rays, spleen, leukocytes, erythrocytes, thrombocytes, 159
- PC, oxidative stress, MDA, CML, biomarkers, malondialdehyde, protein carbonyl, 525
- Peritonectomy, multicystic peritoneal mesothelioma, hyperthermic intra-peritoneal chemotherapy, HIPEC, 153
- Permanent cell lines, HNSCC, CD44, tumor stem cell, 89
- PGE<sub>2</sub>, glycyrrhizin, Chinese medicine, NO, macrophage, 583
- P-glycoprotein, Chalcones, multidrug resistance, MDR reversal, efflux pump, 379
- Pharmacogenomics, ABC transporter, cisplatin, copper transporter, drug resistance, microarray, 279
- Pharmacokinetics, recombinant human factor IX (rhFIX), radiolabeled, biodistribution, pig, 693
- Pharmacokinetics, tamoxifen, 4-hydroxytamoxifen, morin, bioavailability, rats, 391
- Phospholipase A<sub>2</sub>, chinese medicine, Sairei-to, prostaglandin E<sub>2</sub>, cyclooxygenase-2, 571
- Photodynamic therapy, methylene blue, acridine orange, osteosarcoma, 297
- Physical activity, age, fish intake, gender, Omega-3 Index, 131
- Pig, recombinant human factor IX (rhFIX), radiolabeled, biodistribution, pharmacokinetics, 693
- Pineal hormones, interleukin-2, ionizing radiations, radiotherapy, 397
- Plasma cell granuloma, inflammatory pseudotumor, IPT, Inflammatory myofibroblastic tumor, hypopharynx tumor, 817
- Plasma, amyotrophic lateral sclerosis, glutamate, glycine, excitotoxicity, 137
- Plasmocytoma, <sup>18</sup>F-FDG, multiple myeloma, positron emission tomography, detection, 513
- Plasmocytoma, CD137L, interleukin-12, gene therapy, *in vivo*, 337
- Plectin, cytokeratin, hepatocellular carcinoma, staurosporine, apoptosis, 543
- Polymorphism, lipoproteins, coronary artery disease, genetic, ABCA1, VLDL, cholesterol, 187
- Polymorphism, MnSOD, superoxide dismutase, open heart surgery, 147
- Polyunsaturated fatty acids (PUFA), chronic kidney disease (CKD), fatty acid composition, hemodialysis, 609
- Polyurethane sponge, tie-over, skin graft, wound bed, difficult body areas, 503
- Population screening, fragile X syndrome, CGG expansion, gray zone alleles, FMRP, 451
- Portal blood flow, Doppler ultrasonography, meal intake, chronic hepatitis, liver cirrhosis, hyperdynamic syndrome, 509
- Positron emission tomography, <sup>18</sup>F-FDG, multiple myeloma, plasmocytoma, detection, 513
- Pregnancy, breast cancer, mammary cancer, rodent models, estrogen, progesterone, review, 191
- Pregnancy, osteopontin, natural killer cells, progesterone, abortion, 55
- Pretargeting, monoclonal antibodies (MAB), <sup>188</sup>Re, biodistribution, 321
- Preterm birth, nitric oxide, inhibition of nitric oxide synthesis, progestational agents, 447
- Pro-drug, indole-3-carbinol (I3C), diindolylmethane (DIM), activity, review, 441
- Progestational agents, nitric oxide, inhibition of nitric oxide synthesis, preterm birth, 447
- Progesterone, breast cancer, mammary cancer, rodent models, pregnancy, estrogen, review, 191
- Progesterone, osteopontin, pregnancy, natural killer cells, abortion, 55
- Prognosis, aplastic anemia, DNA aneuploidy, flow cytometry, chromosomal abnormality, 837
- Prolactin, breast cancer, Rorschach test, maternal behaviour, HER 2-neu, 845
- Prostaglandin E<sub>2</sub>, chinese medicine, Sairei-to, phospholipase A<sub>2</sub>, cyclooxygenase-2, 571

- Prostaglandin E<sub>2</sub>, *Rikko-san*, Kampo medicine, cyclooxygenase-1, cyclooxygenase-2, nitrosylation, 333
- Prostate cancer, vaccine, radiation therapy, 171
- Prostate, chemotherapy, imaging, lymphoma, dog, 755
- Protease inhibitors, stavudine, color Doppler ultrasonography, carotid, atherosclerosis, HIV, 489
- Protein carbonyl, oxidative stress, MDA, PC, CML, biomarkers, malondialdehyde, 525
- Protein kinase R, RNase L, elastase, nitric oxide, chronic fatigue syndrome, daily functioning, 115
- Proteoglycans, chondroitin sulfate, cancer, modified chondroitin sulfate, review, 385
- Psychoncology, chemotherapy, cortisol rhythm, lymphocytopenia, 257
- Rabbit, Spongostan<sup>®</sup>, foreign body giant cells, cartilage tissue engineering, 203
- Radiation recall, biphasic pulses, cisplatin, cat, fibrosarcoma, 751
- Radiation therapy, vaccine, prostate cancer, 171
- Radiation wound, fibroblasts, MMP, TGF-beta, 1
- Radical scavenging activity, cacao husk lignin, anti-HIV activity, vitamin C, 327
- Radical-scavenging activity, butylmethoxyphenol, BHA, bis-BHA, theoretical parameters, 289
- Radical-scavenging activity, SE, lignin, anti-HIV activity, antibacterial activity, vitamin C, 471
- Radiolabeled, recombinant human factor IX (rhFIX), biodistribution, pharmacokinetics, pig, 693
- Radiosensitizers, NLNQ-1, hypoxic cytotoxins, bis-bioreductive agents, 285
- Radiotherapy, base of tongue cancer, salvage surgery, 803
- Radiotherapy, interleukin-2, ionizing radiations, pineal hormones, 397
- Rana japonica*, 4-*tert*-octylphenol, endocrine disruptors, incubation, frog, 105
- Ras, gene expression, carcinogenesis, *Ha-ras*, *p53*, *c-myc*, MNU, DMBA, mice, 793
- Rat malignant fibrous histiocytoma, 2-methoxyestradiol, apoptosis, rat osteosarcoma, 21
- Rat model, head and neck squamous cell carcinoma, allograft, FDG-PET/CT, 403
- Rat myocardium, IGF-1 isoforms, human skeletal muscle, MGF peptide, MGF antibody, 27
- Rat osteosarcoma, 2-methoxyestradiol, apoptosis, rat malignant fibrous histiocytoma, 21
- Rat thigh infection, *Staphylococcus aureus*, bioluminescence, 667
- Rat, colon cancer, digestive system, aberrant crypt foci (ACF), diethylstilbestrol (DES), 7,12-dimethylbenz[ $\alpha$ ]anthracene (DMBA), 699
- Rat, mammary carcinoma, mammary dysplasia, diethylstilbestrol (DES), endocrine disruptor, 7,12-dimethylbenz[ $\alpha$ ] anthracene (DMBA), neonatal, 207
- Rats, experimental liver cirrhosis, endotoxemia, messenger ribonucleic acid, IGF-I, 655
- Rats, non-invasive stress assessment, corticosterone, ACTH, 435
- Rats, tamoxifen, 4-hydroxytamoxifen, morin, pharmacokinetics, bioavailability, 391
- <sup>188</sup>Re, monoclonal antibodies (MAb), pretargeting, biodistribution, 321
- Recombinant human factor IX (rhFIX), radiolabeled, biodistribution, pharmacokinetics, pig, 693
- Reflux, esophagitis, non-human primates indent, 721
- Regressing tumour tissue, Equine sarcoid, immunotherapy, biological cancer therapy, mitochondrial changes, 519
- Renal cell cancer, interleukin-2, chemotherapy, metastatic disease, 481
- Reperfusion, liver, cold storage, UW, Celsior, sinusoidal endothelial cells, glutathione, 681
- Resistance to chemotherapy, cetuximab, *EGFR* mutations, erlotinib, gefitinib, NSCLC, review, 529
- Respiration, nordihydroguaiaretic acid derivative, tumor cell growth, ATP level, inhibition, cytotoxicity, 353
- Review, animal model, heart failure, cardiac remodelling, 767
- Review, breast cancer, mammary cancer, rodent models, pregnancy, estrogen, progesterone, 191
- Review, cetuximab, *EGFR* mutations, erlotinib, gefitinib, NSCLC, resistance to chemotherapy, 529
- Review, DNA breaks, DNA damage and repair, H2AX, lethal damage, 305
- Review, extracellular matrix, fibrosis, muscle damage, muscle inflammation, transforming growth factor  $\beta$ 1, urokinase-type plasminogen activator, 735
- Review, gastric cancer, advanced and recurrent, adjuvant therapy, new drugs, 273
- Review, heat shock proteins (HSPs), molecular chaperones, anticancer agents, HSP 90, HSP inhibitors, geldamycin, 17-allyl-17-dimethoxygeldanamycin, 311
- Review, indole-3-carbinol (I3C), diindolylmethane (DIM), pro-drug, activity, 441
- Review, non-papillary lesions, urothelium, urinary bladder, immunohistochemistry, 493
- Review, osteochondroma, HMO, exostosis, chondrosarcoma, imaging, 633
- Review, proteoglycans, chondroitin sulfate, cancer, modified chondroitin sulfate, 385
- Review, well-differentiated thyroid carcinoma, thyroid incidentaloma, differential diagnosis, follow-up, serum thyroglobulin levels, <sup>18</sup>F-FDG PET, 109
- Rikko-san*, Kampo medicine, prostaglandin E<sub>2</sub>, cyclooxygenase-1, cyclooxygenase-2, nitrosylation, 333
- RNase L, elastase, protein kinase R, nitric oxide, chronic fatigue syndrome, daily functioning, 115
- Rodent models, breast cancer, mammary cancer, pregnancy, estrogen, progesterone, review, 191

- Rorschach test, breast cancer, prolactin, maternal behaviour, HER 2-neu, 845
- ROS, bee venom (BV), MCF7 cells, apoptosis, caspase, mitochondria, 237
- Sairei-to, chinese medicine, prostaglandin E<sub>2</sub>, phospholipase A<sub>2</sub>, cyclooxygenase-2, 571
- Saliva, HPV, HIV, oral cancer, molecular testing, 599
- Salvage surgery, base of tongue cancer, radiotherapy, 803
- SAR, chlorambucil, 7-keto-steroids, antileukemic activity, steroidal esters, catalytic reduction, 345
- SE, lignin, radical-scavenging activity, anti-HIV activity, antibacterial activity, vitamin C, 471
- Serum thyroglobulin levels, well-differentiated thyroid carcinoma, thyroid incidentaloma, differential diagnosis, follow-up, <sup>18</sup>F-FDG PET, review, 109
- Sesquiterpene, antitumor promotion, *Euonymus* species, dihydro-β-agarofuran, cytomegalovirus, IE antigen expression, 787
- Short review, interstitial pneumonia, drip infusion, megadose vitamin C, dehydroepiandrosterone, cortisol, fortified adrenocortical elements, 263
- Sinusitis, eosinophilic chronic rhinosinusitis, ECRS, HGF, VCAM-1, cell culture, 77
- Sinusoidal endothelial cells, liver, cold storage, reperfusion, UW, Celsior, glutathione, 681
- Skin graft, polyurethane sponge, tie-over, wound bed, difficult body areas, 503
- Skin, *Atelerix albiventris*, lymphoma, surgery, T-cell, 43
- Solar flare, ionizing radiation, space radiation, particle radiation, gamma-rays, spleen, leukocytes, erythrocytes, thrombocytes, 159
- Space radiation, ionizing radiation, solar flare, particle radiation, gamma-rays, spleen, leukocytes, erythrocytes, thrombocytes, 159
- Spirituality, cancer chemotherapy, faith, immunity, lung cancer, 577
- Spleen, ionizing radiation, space radiation, solar flare, particle radiation, gamma-rays, leukocytes, erythrocytes, thrombocytes, 159
- Spongostan<sup>®</sup>, foreign body giant cells, cartilage tissue engineering, rabbit, 203
- SR/CR, cancer-resistant phenotype, litter seriation, 565
- Staphylococcus aureus*, rat thigh infection, bioluminescence, 667
- Stat, T-cell lymphoma, IL-9Rα, strain difference, 713
- Staurosporine, cytokeratin, plectin, hepatocellular carcinoma, apoptosis, 543
- Stavudine, protease inhibitors, color Doppler ultrasonography, carotid, atherosclerosis, HIV, 489
- Steroidal esters, chlorambucil, 7-keto-steroids, antileukemic activity, SAR, catalytic reduction, 345
- Stomach, amyloidosis, baboons, 663
- Strain difference, T-cell lymphoma, IL-9Rα, Stat, 713
- Sulforaphane, apoptosis, cytodifferentiation, granulocytes, macrophages, HL-60 cells, 317
- Superoxide dismutase, polymorphism, MnSOD, open heart surgery, 147
- Suppression, epinastine, eosinophil, activation, 13
- Surgery, *Atelerix albiventris*, lymphoma, skin, T-cell, 43
- Surgery, carboplatin, carcinoid, dog, immunohistochemistry, 759
- Surgical flaps, leptin, survival rate, ischaemia, wound healing, angiogenesis, 247
- Survival rate, leptin, surgical flaps, ischaemia, wound healing, angiogenesis, 247
- Systemic sclerosis, colorectal cancer, paraneoplastic syndrome, 825
- T-cell, *Atelerix albiventris*, lymphoma, skin, surgery, 43
- T-cell lymphoma, IL-9Rα, Stat, strain difference, 713
- T-regulator lymphocytes, anticancer immunity, immunosuppression, lymphocytes, 647
- Tamoxifen, 4-hydroxytamoxifen, morin, pharmacokinetics, bioavailability, rats, 391
- Tenascin-C (TN), astrocytes, central nervous system (CNS), glial fibrillary acidic protein (GFAP), lesion, 409
- 4-Tert-octylphenol, endocrine disruptors, incubation, frog, *Rana japonica*, 105
- TGF-beta, fibroblasts, radiation wound, MMP, 1
- Theoretical parameters, butylmethoxyphenol, BHA, bis-BHA, radical-scavenging activity, 289
- Thrombocytes, ionizing radiation, space radiation, solar flare, particle radiation, gamma-rays, spleen, leukocytes, erythrocytes, 159
- Thyroid incidentaloma, well-differentiated thyroid carcinoma, differential diagnosis, follow-up, serum thyroglobulin levels, <sup>18</sup>F-FDG PET, review, 109
- Tie-over, polyurethane sponge, skin graft, wound bed, difficult body areas, 503
- TIL, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, tumor infiltrating lymphocytes, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Transforming growth factor β1, extracellular matrix, fibrosis, muscle damage, muscle inflammation, urokinase-type plasminogen activator, review, 735
- Tumor cell growth, nordihydroguaiaretic acid derivative, respiration, ATP level, inhibition, cytotoxicity, 353
- Tumor infiltrating lymphocytes, NY-ESO-1, cancer-testis antigens, CTAs, neoplasm associated markers, NAMs, childhood astrocytoma, ASTR, childhood medulloblastoma, MED, immunophenotype, IP, TIL, immunocytochemistry, monoclonal antibody, MoAB, antigen retrieval, 83
- Tumor stem cell, HNSCC, permanent cell lines, CD44, 89

- Tumorigenesis BALB/c mice, curcumin, DHPN  
(*N*-bis(2-hydroxypropyl)nitrosamine, *in vivo*, 781
- Umbilical reconstruction, ectopic endometriosis, 811
- Urinary bladder, non-papillary lesions, urothelium,  
immunohistochemistry, review, 493
- Urokinase-type plasminogen activator, extracellular matrix,  
fibrosis, muscle damage, muscle inflammation,  
transforming growth factor  $\beta$ 1, review, 735
- Urothelium, non-papillary lesions, urinary bladder,  
immunohistochemistry, review, 493
- UW, liver, cold storage, reperfusion, Celsior, sinusoidal  
endothelial cells, glutathione, 681
- Vaccine, radiation therapy, prostate cancer, 171
- Validation energy index point score, chronic fatigue  
syndrome, 799
- VCAM-1, eosinophilic chronic rhinosinusitis, ECRS, HGF,  
cell culture, sinusitis, 77
- Vitamin C, cacao husk lignin, radical scavenging activity,  
anti-HIV activity, 327
- Vitamin C, SE, lignin, radical-scavenging activity, anti-  
HIV activity, antibacterial activity, 471
- VLDL, lipoproteins, coronary artery disease, genetic,  
polymorphism, ABCA1, cholesterol, 187
- WEHI-3 leukemia cells, curcumin, BALB/c mice,  
cytotoxicity, 63
- Well-differentiated thyroid carcinoma, thyroid  
incidentaloma, differential diagnosis, follow-up, serum  
thyroglobulin levels,  $^{18}\text{F}$ -FDG PET, review, 109
- Wound bed, polyurethane sponge, tie-over, skin graft,  
difficult body areas, 503
- Wound healing, leptin, surgical flaps, survival rate,  
ischaemia, angiogenesis, 247
- Wound repair, aged, mice, endothelial cells, nitric oxide,  
aortic rings, angiogenesis, 673



## Authors Index

(Figures refer to page numbers)

- Abelson KSP, 435  
Adamopoulou M, 599  
Agnantis NJ, 633  
Ahmad R, 525  
Ahmad R, 837  
Ahn K-M, 593  
Alfano C, 503  
Al-Nahas A, 109  
Amano S, 471  
Amaral L, 69  
Amasaki Y, 713  
Ambrosini V, 513  
Ambrosino G, 509  
Anagnostou E, 529  
Anagnostoulis S, 247  
Anastasakis E, 617  
Andreadou E, 137  
Androulakis G, 269  
Antal T, 793  
Ardavanis A, 825  
Arnaud E, 247  
Arsan S, 147, 477  
Arsenou ES, 345  
Asano K, 13, 687  
Asimakopoulou AP, 385  
Assin R, 755, 759  
Aubry K, 403  
Aust W, 77  
Bacchi G, 123  
Bai M, 633  
Balapure AK, 837  
Baldi A, 43, 47, 51, 751, 755, 759, 821  
Balestra A, 257, 577  
Banti E, 109  
Baratti D, 153  
Barnes J, 77, 549  
Bartolacelli E, 845  
Batovska D, 379  
Bauer M, 793  
Bay B-H, 311  
Becker MI, 353  
Bellacosa C, 489  
Beqaj SH, 799  
Bertoglio A, 845  
Bertone V, 681  
Bessede JP, 403  
Bianchi A, 821  
Biber Muftuler FZ, 93  
Blatza D, 529  
Bloching M, 77  
Bloomer WD, 285  
Bodey B, 83  
Bodey V, 83  
Boncz I, 793  
Borggreffe M, 143  
Boschian A, 565  
Bozkurt N, 477  
Bradlow HL, 441  
Braun T, 77  
Brera G, 397  
Brivio F, 257, 397, 577, 647, 845  
Brunetti B, 821  
Buccheri EM, 811  
Budán F, 793  
Bufalini M, 47  
Bunyaratvej A, 363  
Buset J, 179  
Cabras A, 153  
Cacciapaglia F, 509  
Cantelli-Forti G, 317  
Capecchi A, 123  
Cardelli P, 751, 759  
Carlsson H-E, 435  
Caruso G, 43, 751  
Castellucci P, 513  
Cavo M, 513  
Cegielski M, 203  
Chang C-H, 693  
Chang H-Y, 369  
Chang S-J, 63, 369  
Chang T-J, 693  
Chang Y-H, 63, 223  
Chao W-T, 543  
Charalambous P, 825  
Charpidou A, 529  
Chatzigeorgiou A, 767  
Chen G-W, 215, 223, 237  
Chen J-C, 215  
Chen J-S, 369  
Chen Y-S, 215  
Cheng C-C, 457, 543  
Chiba H, 571  
Chirianni A, 489  
Chistofidou C, 451  
Chiu T-H, 729, 781  
Chiummariello S, 503, 811  
Cho K, 231  
Cho YB, 651, 763  
Choi CH, 763  
Choi J-S, 391  
Choi SH, 231  
Chokchaichamnankit D, 363  
Chou T-K, 693  
Choung P-H, 593  
Chu T-H, 215  
Chung J-G, 63, 215, 223, 237, 369, 729, 781  
Cianciolo G, 123  
Citro G, 43, 47, 51, 751, 755, 759  
Codini C, 51  
Colciago M, 257  
Colí L, 123  
Colombo E, 845  
Comai G, 123  
Coutrakon GB, 159  
Cseh J, 793  
Cumsille MA, 353  
Cuna V, 123  
D'Avino A, 759  
Dalmastris V, 123  
Dannhardt G, 363  
D'Avino A, 43, 51  
De Gado F, 503  
De Ioannes A, 353  
De Luca A, 51  
De Meirleir K, 115  
De Schutter G, 115  
Del Corso A, 447  
Del Monte G, 481  
Delfino S, 821  
Deng B, 55  
Deraco M, 153  
Derka S, 621  
Dessy LA, 503, 811  
Di Bella S, 647  
Di Nucci A, 681  
Dick Jr EJ, 9, 101, 613, 663, 721, 725  
Dobrina A, 509  
Domeyer PJ, 269  
Donta I, 603, 621  
Dosios T, 603  
Dotsinsky I, 47, 51, 751  
Dziegiel P, 203, 463  
Economides DL, 617  
Efferth T, 279  
Efthimiadou A, 587  
Eguchi T, 707  
Eivazi B, 253  
Ember I, 793  
Engi H, 379, 787  
Enginar H, 93  
Ergen A, 147, 187, 477  
Esposito V, 489  
Eto Y, 409  
Eyman D, 673  
Fanti S, 513  
Faundez M, 353  
Feroce F, 47  
Ferreira J, 353  
Ferrigno A, 681  
Ferroni P, 481  
Fimognari C, 317  
Fitzgerald JT, 799  
Flyvbjerg A, 655  
Fodor J, 803  
Folz BJ, 253  
Forssell L, 721  
Fossile E, 481  
Fousteris MA, 345  
Franchi R, 513  
Freitas I, 681  
Frémont M, 115  
Fryssira H, 451  
Fujii H, 21  
Fujioka S, 131  
Fujisawa S, 289  
Fujita T, 609  
Fujiwara M, 707  
Fukamachi H, 327  
Fumagalli G, 257  
Fumagalli L, 153, 257, 397, 577, 647, 845  
Furuta A, 13  
Furuya A, 13  
Gagliardi DN, 811  
Galani V, 633  
Gao W, 55  
Gargiulo M, 489, 759  
Gehrking E, 817  
Gejima K, 207, 699  
Germann G, 1  
Giannini G, 47  
Göbel G, 793  
Goessler UR, 1  
Gogbashian A, 109

- Goldkuhl R, 435  
 Gong F, 55  
 Görmüş U, 477  
 Gorschluter M, 337  
 Gracza T, 793  
 Graefe H, 817  
 Grassetto G, 513  
 Gridley DS, 159, 423  
 Grønnebæk H, 655  
 Gross MD, 513  
 Grossman TH, 667  
 Guadagni F, 481  
 Gyöngyi Z, 793  
 Halapas A, 27, 767  
 Hallamaa RE, 519  
 Hamazaki K, 131  
 Hamazaki T, 131  
 Han S-M, 237  
 Hasegawa H, 327, 471  
 Hashimoto K, 333, 571, 583  
 Hau J, 435, 565  
 Hisamitsu T, 687  
 Ho C-C, 457, 543, 781  
 Ho L-C, 457, 543  
 Hohmann J, 787  
 Honoki K, 21  
 Horie N, 333, 571, 583  
 Hörmann K, 77, 415, 549  
 Hrelia P, 317  
 Hsia T-C, 781  
 Hsieh W-T, 223  
 Hsu S-C, 729  
 Hsu Y-H, 457, 543  
 Huang A-C, 781  
 Huang G-J, 369  
 Huang J, 629  
 Huang W-W, 9, 63, 101, 613, 663, 721, 725  
 Ikarashi T, 327  
 Ikeshima-Kataoka H, 409  
 Iliopoulos DC, 537  
 Ip S-W, 237, 781  
 Isbir S, 147, 187, 477  
 Isbir T, 187, 477  
 Ishigamori-Suzuki R, 557  
 Ito S, 289  
 Ito Y, 707  
 Itomura M, 131  
 Ivanova A, 379  
 Izykowska I, 203  
 Jacquet P, 179  
 Jang CH, 651, 763  
 Jang H-S, 593  
 Jin W-G, 629  
 Kaden JJ, 143  
 Kadir RA, 617  
 Kadoma Y, 289  
 Kaina B, 279  
 Kakinuma S, 713  
 Kalaitzidaki M, 451  
 Kalkeri G, 667  
 Kamper E, 767  
 Kanai K-I, 13, 687  
 Kanamoto T, 327, 471  
 Kanavakis E, 451  
 Kaneko T, 333, 571, 583  
 Kang SS, 231  
 Kapaki E, 137  
 Karamanos NK, 385  
 Karatzias G, 633  
 Karayannacos PE, 603  
 Karayiannakis A, 247  
 Karres N, 673  
 Kásler M, 803  
 Kato T, 333, 571, 583  
 Katsaros N, 137  
 Kawaguchi H, 105, 207, 699  
 Kawashima H, 207, 699  
 Khan S, 109  
 Kido A, 21  
 Kikuchi H, 471  
 Kim G, 231  
 Kim J-H, 231  
 Kim Myounghwan, 231  
 Kim Mihye, 557  
 Kim Mi-Jung, 593  
 Kim Myung-Jin, 593  
 Kim Y, 337  
 Kingman CE, 617  
 Kirihara Y, 131  
 Kisro J, 831  
 Kitsiou S, 451  
 Kitsoulis P, 633  
 Kobayashi K, 131  
 Kobayashi Y, 713  
 Koch J, 565  
 Kodama M, 263  
 Koderia Y, 707  
 Koellensperger E, 1  
 Koike M, 707  
 Kokkori A, 621  
 Kokotis P, 137  
 Kolialexi A, 451  
 Komokata T, 699  
 Kong B, 55  
 Konkimalla VB, 279  
 Korkolis DP, 247  
 Koss P, 159  
 Kostova I, 379  
 Koutsilieris M, 27, 735, 767  
 Koutsourea AI, 345  
 Kramb J-P, 363  
 Kremer T, 1  
 Kubota T, 273  
 Kumar A, 837  
 Kumar SD, 311  
 Kumasaka R, 609  
 Kuo C-L, 729  
 Kuo LJ, 305  
 Kuroshita R, 471  
 Kusama K, 333, 571, 583  
 Kusamura S, 153  
 Kusuzaki K, 297  
 La Manna G, 123  
 Laghi V, 509  
 Lai Y-S, 457, 543  
 Lambrecht FY, 93  
 Lambropoulou M, 247, 587  
 Laterza B, 153  
 Lazaris A, 621  
 Lee B-K, 593  
 Lee CA, 617  
 Lee H-R, 593  
 Lee J-H, 593  
 Lee JY, 231  
 Lee MJ, 231  
 Lee T-W, 693  
 Lenzi M, 317  
 Lerner AM, 799  
 Leweling H, 143  
 Li Y-C, 63  
 Liang L, 55  
 Liao S-S, 237  
 Liapakis IE, 247  
 Libitaki G, 137  
 Lillo A, 489  
 Lin C-C, 729  
 Lin H-J, 215  
 Lin J-P, 223, 237  
 Lin M-L, 237, 729  
 Lin M-W, 237  
 Lin S-S, 63, 223, 729, 781  
 Lin S-Y, 63, 237, 729, 781  
 Lin T-P, 781  
 Lirdprapamongkol K, 363  
 Lissoni P, 257, 397, 577, 647, 845  
 Liu J, 55  
 Liu K-C, 215  
 Liu Y-H, 457, 543  
 Lodi F, 513  
 Lombardi A, 123  
 Loukeri S, 621  
 Lu H-F, 63, 215, 237  
 Lu K-W, 215  
 Lumachi F, 509, 807  
 Luo-Owen X, 159  
 Lwin ZM, 311  
 Madej JA, 463  
 Maeda Y, 327  
 Maggi P, 489  
 Major T, 803  
 Makinde AY, 159  
 Mani N, 667  
 Maridaki M, 27, 735  
 Mariolis A, 269  
 Mariotti S, 481  
 Marotta F, 447  
 Marrozzini C, 123  
 Martins M, 69  
 Matsubara T, 297  
 Matsumine A, 297  
 Matsuoka Y, 191  
 Mavrou A, 451  
 Maya JD, 353  
 Mazza U, 845  
 McGregor N, 115  
 McQuarrie SA, 321  
 Medine EI, 93  
 Meeus M, 115  
 Meeusen R, 115  
 Mellone P, 759  
 Mercer JR, 321  
 Messina G, 257, 577, 647, 845  
 Metaxotou C, 451  
 Mikhailidis DP, 537  
 Miller GG, 321  
 Miller ML, 9  
 Miyamoto S, 557  
 Mochizuki Y-I, 13  
 Molnár J, 379, 787  
 Monarca C, 503  
 Monteil J, 403  
 Montini G, 513  
 Morello A, 353  
 Moulakakis KG, 603  
 Moulavassili P, 621  
 Mouzakioti E, 269  
 Mudrov N, 47, 51, 751  
 Murakami A, 557  
 Murakami R, 609  
 Nagasawa T, 131  
 Nagata R, 207  
 Naim R, 77, 415, 549  
 Nakagama H, 557  
 Nakamura N, 609

- Nakamura T, 297  
 Nakamura Y, 471  
 Nakanishi H, 707  
 Nakao A, 707  
 Nakashima H, 327, 471  
 Nakayama G, 707  
 Nanni C, 513  
 Naumann A, 77  
 Neefs M, 179  
 Neri D, 681  
 Neukam FW, 599  
 Nielsen SS, 655  
 Nijs J, 115  
 Nikolaropoulos SS, 345  
 Nikolettos NK, 587  
 Nishimura M, 713  
 Nitsch SM, 89  
 Nkenke E, 599, 621  
 Nomura A, 327, 471  
 Nonni A, 269  
 Nowak M, 463  
 Nowrasteh G, 793  
 Oberna F, 803  
 Ocsovszki I, 379  
 Ohashi N, 707  
 Oizumi T, 471  
 Okumura K, 609  
 Onesti MG, 811  
 Orlando R, 807  
 Orphanos G, 825  
 Orrego A, 613  
 Osawa H, 609  
 Osawa K, 327  
 Oyama A, 263  
 Pagonopoulou O, 587  
 Pagotto A, 43  
 Pairas GN, 345  
 Palakurthi S, 321  
 Pancaldi L, 123  
 Panis V, 599  
 Papachristodoulou P, 603  
 Papadopoulos N, 587  
 Papadopoulou MV, 285  
 Papageorgiou A, 345  
 Papakosta V, 621  
 Papalois A, 767  
 Paraf F, 403  
 Parasi A, 269  
 Paraskevas G, 633  
 Paraskevas GP, 137  
 Paraskevas KI, 537  
 Park H, 763  
 Park IY, 763  
 Parolini D, 257, 577, 647  
 Parushev S, 379  
 Pastore G, 489  
 Patsouris E, 621  
 Pavani M, 353  
 Pázsit E, 793  
 Pecaut MJ, 159, 423  
 Pei R-J, 457, 543  
 Perilli F, 489  
 Perjési P, 793  
 Perrea D, 537, 621, 603  
 Persichetti P, 821  
 Persici E, 123  
 Peters SO, 831  
 Petraki CD, 493  
 Petropoulou O, 137  
 Pettinato C, 513  
 Philippou A, 27, 735, 767  
 Piao Y-J, 391  
 Pissimissis N, 27, 767  
 Plaza C, 353  
 Podhorska-Okolow M, 203, 463  
 Polgár C, 803  
 Poulakou MV, 537, 603  
 Prantner I, 793  
 Pries R, 89  
 Pusztai R, 787  
 Qu X, 55  
 Rampin L, 109  
 Rédei D, 787  
 Reed MJ, 673  
 Regina G, 489  
 Renz H, 253  
 Rescaldani R, 647  
 Richelmi P, 681  
 Riedel F, 1  
 Riedel K, 1  
 Rieneck K, 565  
 Rigatos G, 825  
 Rigaud M, 403  
 Rizvi A, 159  
 Rizzo MI, 503  
 Rollo M, 509  
 Roma E, 451  
 Roselli M, 481  
 Rovelli F, 397, 577, 647, 845  
 Rubello D, 109, 513  
 Rubio CA, 9, 101, 613, 663, 721, 725  
 Ryssel H, 1  
 Safioleas MC, 603  
 Sailes V, 171  
 Saito S, 409  
 Sakagami H, 327, 333, 471, 571, 583  
 Sakata R, 699  
 Sakaue S, 687  
 Satoh K, 327, 471, 583  
 Satonaka H, 297  
 Sauerbier M, 1  
 Saur J, 143  
 Sauter A, 77, 415, 549  
 Sawazaki S, 131  
 Schmidt-Wolf IGH, 337  
 Scuderi N, 503  
 Sel S, 253  
 Sergeantanis TN, 269  
 Sfagos C, 137  
 Sfikas CP, 493  
 Shang Y, 713  
 Shen J-S, 409  
 Sheu M-J, 369, 729  
 Shimada M, 609  
 Shimada Y, 713  
 Shimaya Y, 609  
 Shimizu A, 327  
 Shimoyama T, 333, 583  
 Shin S-C, 391  
 Shintani K, 297  
 Siegel SE, 83  
 Sila-Asna M, 363  
 Simopoulos CE, 247  
 Singh R, 525  
 Singh RK, 525, 837  
 Singh S, 525  
 Sironi A, 153  
 Siswanto H, 435  
 Slater JM, 159  
 Sodha S, 415  
 Sofocleous C, 451  
 Sokolis DP, 603  
 Soo ETL, 311  
 Sotlar K, 817  
 Souda M, 105, 207, 699  
 Sourla A, 27  
 Spugnini EP, 43, 47, 51, 751, 755, 759  
 Spyridonidou S, 621  
 Srisomsap C, 363  
 Stauropoulou A, 767  
 Stavrakakis J, 825  
 Stavropoulou A, 27  
 Stefanaki K, 633  
 Stefoni S, 123  
 Steinke A, 831  
 Stellmacher F, 817  
 Stern-Straeter J, 415, 549  
 Stoelting S, 831  
 Strehl JW, 337  
 Su C-C, 63, 781  
 Suckow MA, 171  
 Sugie S, 557  
 Surarit R, 363  
 Suresh MR, 321  
 Suzuki H, 13, 37, 687  
 Svasti J, 363  
 Syrigos KN, 529  
 Takácsi-Nagy Z, 803  
 Takagi H, 263  
 Takakura Y, 21  
 Tanaka T, 557  
 Taniguchi S, 471  
 Tartaglia A, 681  
 Tekeli A, 147, 187, 477  
 Terakubo S, 327, 471  
 Theocharis AD, 385  
 Thomsen KL, 655  
 Tiboni GM, 447  
 Timirci Ö, 477  
 Toto V, 821  
 Trefzer T, 831  
 Trenkle T, 89  
 Trinkmann F, 143  
 Tripathi AK, 525, 837  
 Tripathi P, 525, 837  
 Truijen S, 115  
 Tsai M-C, 457, 543  
 Tsangaris GT, 451  
 Tsigris C, 537  
 Tsubura A, 191  
 Tsujiuchi T, 21  
 Tzanakakis GN, 385  
 Tzilalis B, 269  
 Uchida A, 297  
 Uehara N, 191  
 Umekita Y, 105, 207, 699  
 Unak P, 93  
 Utsumi K, 327  
 Uwechie V, 509  
 Vaghi M, 647  
 Vairaktaris E, 599, 621  
 Vairretti M, 681  
 Van Hoof E, 115  
 Vankerkom J, 179  
 Varga Z, 793  
 Varjas T, 793  
 Vassiliou S, 621  
 Vassilopoulos D, 137  
 Vezzo R, 647  
 Vigore L, 577, 647  
 Vilstrup H, 655  
 Vishwakerma AL, 837  
 Viveiros M, 69  
 Vlachos IS, 603  
 Vylliotis A, 621

Wagner T, 831	Wu C-H, 369	Yasui Y, 557	Zabel M, 203
Wang L-S, 629	Wu C-T, 629	Yeh C-C, 215	Zagouri F, 269
Wang W, 629	Wu Y-H, 693	Yeh K-T, 457, 543	Zamagni E, 513
Watanabe So, 37, 687	Yamabe H, 609	Yilmaz H, 147	Zardi EM, 509
Watanabe Shigeru, 471	Yamada N, 687	Yip GWC, 311	Zazzera F, 43
Watase F, 687	Yamamoto M, 327	Yokoe I, 289	Zhang H, 667
Weissmann J, 143	Yan M, 171	Yokoyama H, 707	Zhang W, 55
Werner JA, 253	Yang C-Y, 693	Yoshida H, 105, 207, 699	Zhang Y, 55
Wheeler J, 171	Yang J-S, 63, 215, 223, 237	Yoshikawa T, 207	Zhang Y-R, 629
Wiegand S, 253	Yang L-X, 305	Yoshitani K, 21	Zhang Y-Y, 629
Wilson J, 321	Yang M, 55	Yoshizawa K, 191	Zhao S, 629
Wilson MR, 537	Yang M-D, 729	Yu C-S, 223, 781	Zhao Z, 629
Wittkopf N, 89	Yang Q, 55	Yu F-S, 223	Zhu X-L, 629
Wollenberg B, 89, 817	Yang Y, 55	Yuan B, 629	Zis V, 137
Wolter WR, 171	Yano K, 327	Yuasa S, 409	Ziske C, 337
Wu C-C, 223, 729	Yapjakis C, 599, 621	Yuri T, 191	Zografos GC, 269

## **Errata**

Volume 21, No 5, pages 797:

The names of the third and fifth authors should read:

A.J. KARAYIANNAKIS<sup>2</sup>  
M. LAMBROPOULOU<sup>4</sup>

Volume 21, No 6, page 957:

The name of the fifth author should read:

GAURAV ARORA<sup>1</sup>

Volume 22, No 2, pages 247:

The name of the third author should read:

A.J. KARAYIANNAKIS<sup>2</sup>

Volume 22, No 4, pages 529:

The name of the third author should read:

VALSAMO ANAGNOSTOU

## Instructions to Authors

*General Policy.* IN VIVO is a multidisciplinary journal designed to bring together high quality original works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; and (c) development and characterization of models for biomedical research. A main aim of IN VIVO is to ensure the prompt publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report unpublished original works that are not under consideration for publication by another journal, and that they will not be published again in the same form. On publication of a manuscript in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the manuscript passes from the Author(s) to the Journal. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts in terms of grammar and style. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. The *Guiding Principles in the Care and Use of Animals* approved by the Council of the American Physiological Society must be followed. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO for public archiving in PubMed Central.

*Manuscripts.* Two types of papers may be submitted: (i) papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary". Ideally, manuscripts should not exceed fourteen (14) pages (approx. 250 words per double-spaced page) corresponding to four (4) printed pages. Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work, full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words and an abbreviated running title; (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

*Tables.* Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title and legend if appropriate.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined on first usage.

*References.* Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples : 1 Sumner AT : The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones.* O' Malley BW and Chamness GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

*Submission of Manuscripts.* An original and two copies of the manuscript (including all photographs and graphs) should be sent to Dr. J.G. Delinassios, Managing Editor, IN VIVO, Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. A CD-ROM, floppy disc, USB stick or ZIP-disc should also be submitted indicating the computer-processing program. Additionally, for speed of processing, manuscripts may be sent by e-mail to [journals@iiaar-anticancer.org](mailto:journals@iiaar-anticancer.org). Only the original copy of the submitted manuscript will be returned to the Authors upon rejection. The number of recently accepted manuscripts will be entered in the IN VIVO page "Author's Service" as soon as a decision has been reached.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Reprints may be ordered after the acceptance of the paper.

online from January 2009



# in vivo

**International Journal of Experimental and Clinical Pathophysiology and Drug Research**

ISSN: 0258-851X

**General Policy:** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frame of comparative physiology and pathology. Articles are drawn from scientific areas including oncology, pharmacology, chemotherapy, bioterapy, immunology, radiology, toxicology, genetics, cytology, endocrinology, nutrition, comparative pathology, development, biotechnology. Special focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models of biomedical research. The principle aim of IN VIVO is to provide for the prompt publication of accepted articles, within 1-2 months from final acceptance.

IN VIVO supports (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

**Publication Data:** IN VIVO is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in IN VIVO, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

**Annual Subscription Rates** 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008: Institutional, Euro 875.00; Personal, Euro 472.00. Prices include rapid delivery, insurance. Previous volumes of IN VIVO (Vol. 1-21, 1987-2007) are available at 50% discount on the above rates.

**IN VIVO will appear online with Stanford University HighWire Press from the January 2009 issue. For 2009 online/print subscription rates, please visit the IN VIVO-IIAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)**

**Subscription orders:** Orders can be placed at agencies, bookstores, or directly with the publisher. Checks should be made payable to J.G. Delinassios-Athens-Greece. In Japan, contact Woodbell Scope, Inc., 4-22-11, Kitakassai, Edogawa-ku, Tokyo 134, Japan.

Articles in IN VIVO are regularly indexed in bibliographic services, including Index Medicus, PUBMED/MEDLINE, Biological Abstracts, BIOSIS, Chemical Abstracts, Excerpta Medica, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datastar, BRS), Reference Update (I.S.I.), Research Alert (I.S.I.), BioBase, MedBase, Investigational Drugs Database, VINITI Abstracts Journal, PubsHub.

The Editors and Publisher of the journal IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by IN VIVO, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0258-851 X 2008 \$2.00 + .40.

**Correspondence** (subscription orders, reprint orders, disposition of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to: Dr. J.G. Delinassios, Managing Editor.

**Editorial Office:** International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389.

**E-mails:**

**Editorial Office:** [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

**Managing Editor:** [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org)

**For more information about IN VIVO and the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, please visit the IIAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)**